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Introduction and Outline of the Thesis 
INTRODUCTION 
Breast cancer is by far the most common form of cancer and, together with 
carcinoma of the lung, the leading cause of cancer-related deaths in European 
women today1. In the Netherlands, over 12,000 new patients with breast 
cancer were diagnosed in 2005 while 3322 patients died of this disease2. 
In recent years breast cancer treatment has gradually shifted from 
aggressive surgical treatment to minimally invasive surgical procedures. The 
introduction of mass screening programs resulted in the earlier detection of 
breast cancers, which brought about a change in stage distribution. These 
smaller breast lesions made room for less aggressive treatment options. Besides 
this rearrangement in stage distribution, the addition of adjuvant chemotherapy 
and radiotherapy have made less invasive treatment possible3. An excellent 
example of this shift in treatment is the sentinel node (SN) technique as an 
alternative for axillary lymph node dissection (ALND) for staging in breast 
cancer. An overview of the history, technique, validation and indications of the 
SN procedure will be given in this chapter, as well as the aims of this thesis, 
following from this overview. 
History 
In the early 1900's Halsted formulated the theory that a tumour gradually 
metastasizes through lymphatic channels to regional lymph nodes before 
hematogenic dissemination takes place. Since then regional lymph node 
dissection has always been an integral part of breast cancer treatment. In 
accordance with Halsted's concept, breast cancer was treated with radical 
mastectomy, in which the breast, axillary lymph nodes and the pectoral muscle 
were dissected, followed by the supra-radical mastectomy, whereby, in addition 
to the axillary lymph nodes, the internal mammary nodes were removed. After 
a period of several decades during which this radical surgery was advocated, a 
new era of less invasive treatment emerged, as randomized clinical trials had 
failed to demonstrate survival benefit of the supra-radical surgical procedure. 
In 1948 Patey introduced the modified radical mastectomy in which the 
pectoral muscle was spared. In 1981 breast conserving treatment was 
advocated by Veronesi. All along, axillary lymph node dissection remained an 
essential part of the treatment: for staging, local regional control and an 
indicator of the need for adjuvant therapy. 
In 30% to 40% of patients with curable breast cancer metastases in the 
axilla are found. Axillary clearance in this group provides regional tumour 
control. However, the morbidity of ALND is considerable: high percentages of 
9 
Chapter 4 
chronic lymphedema (6-56%), pain (16-55%), sensibility disorders (58-81%) 
and dysfunction of the shoulder and arm (14-32%) are reported, depending on 
the definitions used4. In patients with a tumour negative axilla, who make up 
60-70% of all patients, lymph node dissection has no additional value. With SN 
biopsy it is now possible to offer this group of patients an accurate staging 
without the morbidity of axillary clearance. 
In 1993 Krag was the first to describe the SN biopsy technique in breast 
cancer5. He injected a radioactive tracer around the tumour. The sentinel lymph 
node was localized during surgery by measuring the radioactivity with a 
gamma probe. Based on the intradermal injection technique used by Morton 
for melanomas, Giuliano introduced a peritumoural injection technique with 
blue dye6"8. Albertini advocated the combination of both techniques. Borgstein 
simplified the sentinel lymph node technique by showing that the 
intracutaneous blue dye injection identified the same axillary lymph nodes as 
the peritumoural radioactive tracer injection9. 
The concept 
The sentinel lymph node is the first lymph node upon which the primary 
tumour drains. This lymph node will be the first lymph node to harbour 
metastases. In case of a tumour negative SN, lymphatic metastasizing has not 
(yet) occurred. 
The technique 
In a one or two day protocol a radioactive tracer is injected in the breast. 
Preoperative lymphoscintigraphy is helpful by visualizing location and number 
of axillary and non-axillary SNs. Under general or local anaesthesia according 
to the preoperative lymphoscintigraphic images and after injecting a blue dye 
as a second tracer, the radioactive and/or blue SN can be found and removed. 
Both "isosulfan blue" and "patent blue V" can be used for lymphatic mapping, 
depending on local availability. Moreover, occasional reports about the use of 
other blue dyes have been published. 
Several studies have shown that the combination of a preoperative 
lymphoscintigraphy and the intra operative use of blue dye and a gamma probe 
gives the best results10. 
However, sometimes the lymphatic mapping procedure fails, because of 
insufficient or absent radioactive tracer uptake in the lymph nodes. Because a 
negative preoperative lymphoscintigraphy is predictive for failure of 
intraoperative SN identification, faint- or non-visualization of hotspots on 
lymphoscintigraphic imaging frequently results in the need to perform ALND11. 
10 
Introduction and Outline of the Thesis 
Chapter 2 provides the results of a study which explored the value of additional 
tracer injection to increase the technical success rate of the SN procedure in 
case of a vague or negative lymphoscintigraphy. In addition factors were 
identified that are associated with inadequate visualization of hotspots. 
There is still debate concerning the location of the tracer injection. Based 
on the anatomic embryology of the breast, the skin overlying the breast and the 
breast parenchyma share the same lymphatic drainage to the axillary nodes9. 
Therefore, the site of tracer injection does not influence the detection of the 
axillary SN. Various injection sites for the radiocolloid are described with good 
results, such as intracutaneous, subareolar, peritumoural, intratumoural, 
subtumoural and periareolar injection sites. Advocates of the intracutaneous 
injection technique emphasize the simplicity of the technique and the rapid 
flow through the lymphatic channels, which make the one day protocol short 
and simple. 
Advocates of the peritumoural and intratumoural injection site stipulate 
that this technique provides a more precise image of the drainage pathways of 
the tumour. 
Lymph drainage to the internal mammary chain is virtually absent after 
intradermal injections. But lymphoscintigraphy can visualize internal mammary 
nodes after peri-, intra- or subtumoural tracer injection, enabling internal 
mammary SN biopsy12"14. 
There is ongoing debate concerning the particle size of the different 
radioactive tracers. Smaller particles flow more easily through the lymphatics 
and are retained in the macrophages of the lymph node for a relative short 
period, as compared to larger colloids. In the Netherlands Tc-99m nanocolloid 
is used. This tracer combines easy gamma detection with rapid accumulation in 
the sentinel lymph node. 
There is also discussion concerning the amount of radioactivity used. The 
amount of radioactivity in the literature varies from 37-370 MBq (1-10 mCi)15. 
Radiation safety for the medical staff versus optimal detection of the radioactive 
lymph nodes and logistic reasons influence the amount of tracer used. The 
radiation exposure for the patient is negligible as compared to adjuvant 
radiotherapy for breast conserving therapy and irrelevant in case of a 
mastectomy. Pijpers et al. proved that the radiation exposure for the surgeon 
and the staff, using 37MBq (1 mCi), stays within the limit of 1 mSv per year1'1. 
If we extrapolate the knowledge from this study to our own technique, using 
370 MBq, a surgeon can perform over 650 SN procedures per year and stay 
well within the legal limit of 1000(.iSv. 
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Histopathological examination of the SN consists of hematoxylin/eosin 
staining, serial sectioning and immunohistochemical (IHC) staining17. 
Compared to ALND, the SN procedure enables improved staging, because the 
pathologist can focus on one node or a few at the most, instead of up to twenty 
nodes. By means of specific techniques, e.g. IHC, micrometastases can now be 
detected, which previously remained undetected and have resulted in stage 
migration18. The prognostic relevance of micrometastases in breast cancer is 
subject of ongoing studies. 
Indication and exclusion criteria for SN biopsy 
Indications and exclusion criteria for the use of SN biopsy have not fully 
crystallized yet. Currently, SN biopsy is applied to >70% of breast cancer 
patients in The Netherlands19. Before performing a SN procedure, a 
preoperative clinical and ultrasound examination of the axilla and fine needle 
aspiration of suspect nodes should be performed. This will reduce the risk of 
false negative results due to massive tumour infiltration in the lymph node. 
Groups for which the use of SN biopsy is debated are patients with ductal 
carcinoma in situ (DCIS), patients with a previous excisional biopsy, patients with 
recurrent breast cancer and patients who received neo-adjuvant chemotherapy. 
• DCIS is a non-invasive cancer which does not metastasize. However, in 
approximately 17% of the resected DCIS specimens an invasive 
component is found, which necessitates staging. The Dutch guideline for 
breast cancer (NABON richtlijn) does not recommend SN biopsy in case 
of grade I DCIS. In case of extended and/or high grade DCIS (grade II and 
III) a SN biopsy should be considered20. 
• Previous excisional biopsy is also considered an exclusion criterion due to 
potential disruption of lymphatic tracts. In Chapter 3, the results are 
presented of 88 patients undergoing a SN procedure after previous 
excisional biopsy. 
• Until now, preoperative radiotherapy to the breast is considered to be an 
absolute exclusion criterion for SN biopsy. 
• There is still debate considering SN biopsy following neo-adjuvant 
chemotherapy. In patients with T3/T4 tumours, for whom neo-adjuvant 
chemotherapy is most often considered, the sentinel node procedure may 
be less reliable because of the risk of massive tumour infiltration. In 
addition, chemotherapy induces cellular necrosis, which complicates 
pathological examination. However, recent studies have shown good 
results in patients receiving neo-adjuvant chemotherapy21. 
• Mastitis carcinomatosa remains an exclusion criterion22. 
12 
Introduction and Outline of the Thesis 
Validation and long term results 
Many studies concerning the concept, validation and feasibility of the SN 
procedure in breast cancer have been performed6'8"10,2 '"27. 
Validation studies confirm that SN biopsy, independent of the technique 
used, accurately predicts the nodal status of the axilla. After validation of the 
institution and the surgeon axillary clearance can be omitted in case of a 
tumour negative SN. To do so, the aforementioned studies recommend an 
identification rate and a sensitivity of more than 95%, resulting in a false 
negative rate of less than 5%. 
The first long term results in this group of patients are currently available. 
Chapter 4 describes the follow-up results of SN negative patients who did not 
receive elective ALND. Special attention was paid to axillary recurrence and 
possible reasons for this relapse. 
Internal mammary SN biopsy 
The technique of lymphatic mapping inevitably confronts us with the 
visualization of SNs outside the axilla. This has renewed the interest in internal 
mammary lymph drainage and the question of its clinical relevance. Surgical 
series from the 1950s showed that one third of breast cancer patients had IMN 
involvement, with a higher risk in patients with medial tumours and/or positive 
axillary nodes. The presence of internal mammary metastases has similar 
prognostic importance as axillary nodal involvement2". However, after three 
randomized trials, which showed no survival benefit from extended 
mastectomy compared with radical or modified radical mastectomy, IMN 
dissection was largely abandoned. Given the prognostic significance of nodal 
positivity in the internal mammary chain, harvesting of the internal mammary 
nodes, based on lymphoscintigraphy, will have implications for staging and 
adjuvant treatment12,29. Nevertheless, when lymphatic mapping reveals 1M 
drainage, staging of these nodes is not performed routinely, thus discarding 
additional staging information. 
The experience in a 9 years period, in which 1MSN biopsy was performed on 
a routine basis in patients with primary breast cancer is presented in Chapter 5. 
The clinical relevance of IMSN biopsy, in terms of survival, is questionable. 
Whether radiotherapy to the IM chain or adjuvant systemic therapy is beneficial 
to high risk subgroups of breast cancer patients with IM metastases is unclear. 
In an attempt to answer this question, treatment outcome of patients with IM 
lymph node metastases, who received tailored adjuvant treatment regimens 
were evaluated, of which the results are presented and discussed in Chapter 6. 
The next two chapters deal with technical aspects and refinement of IMSN 
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biopsy. As discussed above, intraparenchymal tracer injection is essential to 
visualize drainage to the IM lymph nodes. In addition to the injection site, other 
factors can influence IM drainge. In Chapter 7 the effect of different time 
intervals between radioactive tracer injection and lymphoscintigraphy on 
visualization of IMSNs is evaluated. 
The retrieval of IMSNs is often technically more challenging as compared 
to axillary SN biopsy and is associated with lower identification rates5. Failure 
in harvesting IM SNs is correlated with their small size, difficult anatomical 
localization, or limited radioactive tracer uptake4. SPECT/CT (Single-Photon 
Emission Computed Tomography/Computed Tomography) is a recent non-
invasive technique that combines the functional information of SPECT with the 
anatomical information provided by CT. Chapter 8 gives the results of a study, 
in which it was investigated whether this new technique is beneficial compared 
to lymphoscintigraphy alone, in patients with IM hotspots. 
AIMS OF THE THESIS AND DATA COLLECTION 
In summary, the aims addressed in this thesis are to: 
Chapter 2: ascertain the value of additional tracer injection to increase the 
technical success rate of the SN procedure in case of a vague or 
negative lymphoscintigraphy. 
Chapter 3: determine whether patients with previous excisional biopsy are 
eligible for SN biopsy. 
Chapter 4: evaluate the accuracy of the SN procedure by focusing on the 
outcome of SN negative patients who did not receive elective 
ALND. 
Chapter 5: demonstrate the risk of IM lymph node metastases in case of IM 
hotspots on lymphoscintigraphy and evaluate the relevance of 
IMSN biopsy as a method to improve staging. 
Chapter 6: assess treatment outcome of patients with IM lymph node 
metastases, who received tailored adjuvant treatment regimens. 
Chapter 7: establish the effect of different time intervals between radioactive 
• tracer injection and lymphoscintigraphy on visualization of 
IMSNs. 
Chapter 8: investigate whether SPECT/CT has a significant influence on the 
surgical decision making, as compared to conventional 
lymphoscintigraphy alone, in patients with breast cancer with IM 
hotspots on lymphoscintigraphy. 
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Chapter 2: 1208 patients, 93 with additional tracer injection, 1997-August 2007. Aim: to evaluate the value o( additional tracer injection, 
Chapter 3:138 patients SN with ALND, 1997-jan 2000. Aim: to determine the validity of SN after excision biopsy. 
Chapter 4:656 patients, 343 with negative SN, 1998-May 2004. Aim: to determine the number of axillary recurrences in case of a negative SN. 
BE22-. ... .. 
Chapter 5:1008 patients, 1997-may 2006. Aim: evaluate the clinical relevance of IMSN biopsy to improve staging, 
•nastti...... 
Chapter 6:764 patients, 1997-july 2004. Aim: assess outcome of patients with IM metastases. 
•SB»«»«»'.". • \ ASiagll 
Chapter 7:1997-august 2001,682 patients. Aim: establish the effect of different time intervals on visualization of IMSNs. 
Chapter 8: jan 2006-jan 2008,42 patients. Alms:investigate the additional role of SPECT/CT for IMSNs. •t. >;m 
With the exception of the multicenter study described in chapter 7, ail studies 
described in this thesis are based on the data from the Maasland Hospital (as of 
February 1sl 2009 Orbis Medical Center) in Sittard-Geleen, The Netherlands. 
This prospective, standardized ongoing database was created at the 
introduction of the SN procedure in 1997 in the Maasland Hospital, and 
presently consists of over 1400 patients. All consecutive patients with clinically 
node-negative operable primary breast cancer undergoing SN biopsy were 
included in the database. Except for pregnant women and patients with T4-
tumours, no patients were excluded. Data with regard to patient and tumour 
characteristics, and staging and treatment procedures were documented and 
complete disease-specific follow-up data were obtained. 
The SN technique consisted of an injection of 370 MBq (10 mCi) "mTc-
nanocolloid, either peritumourally or into the breast tissue adjacent to the 
cavity of the previous excisional biopsy. All patients underwent preoperative 
lymphatic mapping following a mean interval of 16 hours (range: 12-18). 
During surgery in all patients attempts were made to harvest both axillary and 
non-axillary SNs, as visualized on lymphoscintigraphy. In phase I of this study 
(137 patients) SN biopsy was followed by completion axillary lymph node 
dissection in all cases. In phase II, after validation of the SN technique in our 
institute, completion axillary lymph node dissection was performed only in 
cases of a tumour-positive axillary SN or non-successful SN procedure. 
15 
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Additional tracer injection to 
improve the technical success rate 
of lymphoscintigraphy for sentinel 
node biopsy in breast cancer 
EM Heuts, FWC van der Ent, HAG van der Pol, MF von Meyenfeldt, AC Voogd 
Ann Surg Oncol 2009, 16:1156-1163 
21 
Chapter 2 
ABSTRACT 
Background 
Sentinel node (SN) biopsy has become the standard of care in the treatment of 
breast cancer. The aim of this study is to determine the value of additional tracer 
injection to increase the technical success rate of the SN procedure and to 
identify factors that influence the ability to visualize hotspots. 
Methods 
From February 1997 to August 2007, 1208 clinically node-negative breast 
cancer patients underwent lymphatic mapping for SN biopsy. The technique 
involved the injection of 370 MBq (10 mCi) Tc-99m -nanocolloid peritumorally. 
In case of insufficient or absent visualization of hotspots 37 MBq (1 mCi) of 
additional tracer was given intracutaneously above the tumour. 
Results 
In 93 patients (7.7%) visualization of hotspots on initial lymphoscintigraphy 
was insufficient (41 patients) or absent (52 patients). The first 14 patients did not 
receive additional tracer injection. In 5 patients, additional tracer did not result 
in successful lymphoscintigraphy, which is correlated with massive nodal 
tumour infiltration. In 33 patients with negative initial lymphoscintigraphy, 
additional tracer injection resulted in secondary SN visualization. 
In 41 patients with faint hotspots on initial lymphoscintigraphy, additional 
tracer injection, by increasing nodal uptake, simplified an accurate SN biopsy. 
Decreased radiotracer uptake in this group was associated with older age and 
high BMI. 
Conclusions 
Additional tracer injection following initial scan failure increases the success 
rate of lymphoscintigraphy during lymphatic mapping in breast cancer, without 
compromising the accuracy. If additional tracer injection does not result in 
secondary SN visualization, gross nodal tumour involvement is often present 
and ALND is mandatory. 
Synopsis 
Faint- or non-visualization of hotspots on lymphoscintigraphy frequently results 
in failure of SN identification. We determined the value of additional tracer 
injection to increase the identification rate of the SN procedure and identified 
factors that influence the visualization of hotspots. 
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INTRODUCTION 
Since the introduction of the sentinel node (SN) procedure in breast cancer, 
many validation studies confirmed the accuracy of the SN biopsy in predicting 
the axillary node status1"0. As compared to axillary lymph node dissection 
(ALND), SN biopsy causes less morbidity and provides the same staging 
information. As a consequence, ALND is nowadays abandoned in case of a 
negative SN biopsy, thereby avoiding unnecessary morbidity and costs associated 
with ALND. 
However, sometimes the lymphatic mapping procedure fails, because of 
insufficient or absent radioactive tracer uptake in the lymph nodes. Because a 
negative preoperative lymphoscintigraphy is predictive for failure of intraoperative 
SN identification, faint- or non-visualization of hotspots on lymphoscintigraphy 
('initial scan failure') frequently results in the need to perform ALND7. 
After having experienced 14 patients with a negative preoperative 
lymphoscintigraphy in the first three years of our study, we started to use 
additional radiocolloid tracer injections as of May 2000, to avoid technical 
failure of the lymphatic mapping procedure. 
The aim of this study is to determine the value of additional tracer 
injection to increase the technical success rate of the sentinel node procedure 
in case of a vague or negative lymphoscintigraphy and to identify factors that 
influence non-visualization of hotspots. 
PATIENTS AND METHODS 
From April 1997 to August 2007, after having received approval of the Local 
Ethical Committee, and after informed consent, a total of 1208 consecutive 
patients with clinically node-negative operable primary breast cancer were 
included in a prospective study on SN biopsy. In Phase I of this study (137 
patients) SN biopsy was followed by completion axillary lymph node dissection 
in all cases. In Phase II, after validation of the SN technique in our institute, 
completion axillary lymph node dissection was performed only in cases of a 
tumour-positive axillary SN or a non-successful SN procedure. From this 
ongoing prospective study we analysed all consecutive patients who showed 
inadequate or absent visualization of hotspots on the initial lymphoscinti-
graphic images (Figures 1-3). 
Our technique of SN biopsy has been described in detail elsewhere2. The 
lymphatic mapping procedure consists of 370 MBq (10 mCi) TC-99m-
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nanocolloid injected peritumorally or in the breast parenchyma surrounding 
the cavity of a previous excisional biopsy. All patients underwent preoperative 
lymphoscintigraphy following a mean interval of 16 hours (range: 12-18). In 
case of initial scan failure, additional radiocolloid tracer injections of 37 MBq 
(1 mCi) Tc-99m-nanocolloid intracutaneously above the tumour were used as 
of May 2000, in order to increase the technical success rate of 
lymphoscintigraphy by obtaining secondary SN visualization. A second 
lymphoscintigraphy was performed 10-15 minutes after the additional tracer 
injection was given. 
In relation to the mapping procedure, radiation exposure guidelines and 
doses were considered for both patients and personnel and were found to be 
well within legal safety limits, as was published previously2. 
In 2002 preoperative ultrasonography of the axilla was introduced in our 
hospital and became standard procedure in combination with FNA cytology in 
case of clinically or radiologically suspicious axillary lymph nodes. Thus, 
patients treated before 2002 did not receive routine ultrasound investigation of 
the axilla. 
During surgery, all axillary and non-axillary SNs were pursued, as 
visualized by lymphoscintigraphy. Intraoperative identification of the SNs was 
based both on blue dye mapping and gamma probe detection. In all cases of a 
failed SN procedure, whether based on secondary scan failure or based on 
intraoperative SN identification failure, ALND was performed, which involved 
at least removal of all level I and II lymph nodes. 
Histopathologic examination of the SN consisted of routine serial sectioning 
with hematoxylin and eosin (H&E) staining, followed by immunohistochemical 
(IHC) staining, whenever routine H&E staining did not reveal metastases. 
Depending on the type of the variable, the Chi-square test or t-test was 
used to compare the characteristics of patients with successful lympho-
scintigraphy and with initial scan failure. 
RESULTS 
In all, 1208 consecutive patients with clinically node-negative breast cancer were 
included in this study. Patient and tumour characteristics are listed in Table 1. 
Initial scan failure 
In 93 patients, the results of preoperative lymphoscintigraphy were 
classified as initial scan failure: 
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in 52 patients, because lymphoscintigraphy showed no axillary hotspots at all 
(negative lymphoscintigraphy) and in 41 patients, because the initial SN 
visualization was considered inadequate (i.e., too faint to allow successful 
intraoperative SN retrieval). The mean age of these 93 patients was 65.8 years, 
as compared to 58.5 years for the remaining group of 1115 patients with clear 
hotspots on initial lymphoscintigraphy (p < 0.0001). 
Within the first three years of the study 14 patients (group A, Table 2) with 
a negative initial lymphoscintigraphy did not receive additional tracer injection 
and consequently ALND was performed in all cases. Of these 14 patients, 10 
were found to have positive lymph nodes, with five of them having more than 
ten involved nodes. The remaining four patients had a negative SN procedure, 
using the blue dye technique, which was confirmed by completion ALND. No 
axillary recurrences were seen in these four patients within a median follow up 
of 80 months. 
As of May 2000, in case of initial scan failure, an additional tracer 
injection of 1 mCi Tc-99m-nanocolloid intracutaneously was routinely used. 
# 
Figure la Figure lb 
Figure 1 Lymphoscintigraphy of patient with initial scan failure (la) and secondary scan failure 
after additional tracer injection (1b) 
Secondary scan failure 
In 5 patients (group B, Table 2) with initial scan failure, following additional 
tracer injection, repeated lymphoscintigraphy still did not show hotspots 
(Figures 1a and 1b). Mean age of these patients was 66.2 years. Successful SN 
harvesting was possible in only one patient, because a (tumour-positive) 
palpable lymph node was found intra-operatively. 
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Table 1 Comparison of characteristics of patients (N=1208) with successful lymphoscintigraphy 
and with initial scan failure 
Characteristic Successful 
lymphoscintigraphy 
(n—1115) 
N 
Initial scan 
failure 
P-value 
(n=93) 
(%) 
Age 
346 31% 10 11% <0.0001 
51-70 544 49% 52 56% 
>70 225 20% 31 33% 
Tumour localization 
Lateral 615 55% 43 46% 0.23 
Medial 395 36% 40 43% 
Central 105 9% 10 11% 
Tumour size 
DCIS/Paget 37 3% 1 1% <0.0001 
TT 653 59% 46 49% 
T2 398 36% 34 37% 
T3 27 2% 12 13% 
Number of positive lymph nodes 
0 676 61% 46 49% <0.0001 
1-3 351 31% 24 26% 
>3 88 8% 23 25% 
Tumour grade 
Good 286 26% 29 31% 0,43 
Moderate 478 43% 39 42% 
Poor 351 31% 25 27% 
Surgery 
Core biopsy 932 84% 77 83% 0,84 
Previous excisional biopsy 183 16% 16 17% 
Estrogen receptor status 
Negative 215 21% 19 22% 0,80 
Positive 823 79% 68 78% 
Missing values 77 6 
Progesterone receptor 
Negative 367 35% 24 28% 0.14 
Positive 670 65% 63 72% 
Missing values 78 6 
IM hotspots on 236 21% 5 5% <0.0001 
lymphoscintigraphy 
BMI 100* 25.5** 93 29.0** <0,0001 
* sample of 100 patients **mean B Ml (Body Mass Index) 
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Axillary dissection was done in all 5 patients and showed a tumour-positive 
axilla in four (80%) of which three patients showed massive tumour infiltration 
of almost all axillary lymph nodes. The only node negative patient in this 
subgroup had no axillary recurrence during a follow up period of 49 months. 
Secondary SN visualization 
In 33 patients (group C, Table 2) with initial scan failure, we noted secondary 
SN visualization on repeated lymphoscintigraphy as a direct result of additional 
tracer injection (Figures 2a and 2b). In these patients mean age was 64.7 years. 
Secondary lymphoscintigraphy clearly showed one or more axillary hotspots, 
which subsequently could be harvested in all cases, showing a positive SN in 
17 patients (52%), all of whom underwent ALND. Massive nodal tumour 
burden, with ten or more tumour-positive nodes, was present in 3 patients only 
(9%). In 15 patients the SN was found to be tumour-negative and no ALND was 
performed. No axillary recurrences were noted during a median follow up of 
27 months in these patients. One patient (5.5%=1/18) in this subgroup had a 
Table 2 Patient and tumour characteristics of patients with initial scan failure (N=93). 
group A: initial scan failure, no additional (racer given 
group B: initial and secondary scan failure 
group C: initial scan failure, successful secondary scan 
group D: enhanced scan after additional tracer injection 
A B C D P-value 
Number of patients 14 5 33 41 
Age (mean) 64.7 66.2 64.7 67.0 
BMI (mean) 29.3 29.1 28.9 28.9 
Tumour size >2 cm 9 5 15 17 0.06 
(64%) (100%) (45%) (41%) 
Ultrasound axilla (n) 1 2 17 23 0.007 
(7%) (40%) (52%) (56%) 
Axillary metastases (%) 10 4 17 16 0.10 
(71%) (80%) (52%) (39%) 
Massive nodal/lymphatic tract infiltration 8 3 3 1 <0.0001 
(57%) (60%) (9%) ( 2 % ) 
Axillary recurrence in node-negative patients - - 0 0 
Median follow up node-negative 80* 49* 27 41 
patients (months) 
*node-negativity confirmed with ALND 
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false-negative SN procedure. A tumour-positive lymph node was found during 
subsequent simple mastectomy. She was given axillary radiotherapy. No 
axillary recurrence was seen thereafter within a 60 months follow up period. 
Figure 2 Lymphoscintigraphy of patient with initial scan failure (2a), but secondary SN 
visualization after additional tracer injection (2b) 
Enhanced lymphoscintigraphy 
In 41 patients (group D, Table 2) with initial scan failure, in which initial 
lymphoscintigraphy showed only a faint hotspot, judged to be insufficient to 
allow successful SN harvesting, additional tracer injection led to increased 
radioactive uptake in the same hotspot (Figures 3a and 3b), rather then 
visualizing additional hotspots. The mean age of these patients was 67.0 years. 
Additional hotspots as a result of additional tracer injection were seen in only 
5 patients (12%). The increased radioactive uptake facilitated SN harvesting, 
which was successful in all cases. A tumour-positive SN was found in 16 
patients (39%), which was not different from the group of 1115 patients with 
clear hotspots on initial lymphoscintigraphy (39%). Only one patient (2.4%) 
had massive tumour infiltration in the axilla, showing all axillary lymph nodes 
to be tumour-positive. No completion ALND was performed in the remaining 
25 patients with a negative SN biopsy. Among these 25 patients again no 
axillary recurrences were found during a median follow up of 41 months. 
Figure 2a Figure 2b 
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Figure 3a Figure 3b 
Figure 3 Lymphoscintigraphy of patient with faint hotspot (3a), but clear hotspot after additional 
tracer injection (3b) 
D I S C U S S I O N 
Because of its high sensitivity to detect nodal metastatic disease and its 
minimally invasive nature, SN biopsy has become the standard of care for 
staging early invasive breast cancer, thereby limiting axillary dissection to 
patients with axillary metastases and sparing node-negative patients the 
morbidity of axillary dissection. However, sometimes the lymphatic mapping 
procedure tends to fail, because of inadequate or even absent radioisotope 
uptake in the SN. This urges the surgeon to perform a complete axillary lymph 
node dissection, which might have been avoided, had the lymphatic mapping 
been successful. 
After having experienced 14 patients with a negative preoperative 
lymphoscintigraphy in the first three years of our study, we started to use 
additional radiocolloid tracer injections as of May 2000, to avoid technical 
failure of the lymphatic mapping procedure. The use of additional tracer 
injection has been previously reported by Cserni et al, in 20 patients". 
Several factors have been identified to influence lymphatic mapping. 
Besides technical factors, like tracer volume, tracer dose, site of tracer injection 
and timing of lymphoscintigraphy imaging, other factors like prior breast 
surgery and upper lateral tumour location, which might hamper lymphatic 
mapping due to shine through, have been reported to influence lymphatic 
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drainage patterns. However, there are three major reasons for initial scan 
failure: extensive nodal tumour infiltration, increased age and increased Body 
Mass Index (BMI). 
Extensive nodal tumour infiltration 
Axillary hotspot visualization is negatively influenced by extensive nodal 
involvement2,9"14. This can be explained by nodal tracer uptake physiology: the 
radioactive tracer is bound to colloid, which is phagocytosed by macrophages 
within the normal lymph tissue of the SN. If the SN, or the afferent lymph tracts, 
show massive tumour infiltration and/or extranodal growth, the lymph flow 
might be blocked, or there might be not enough functional lymph tissue left to 
phagocytose the radiocolloid. Thus, if a SN is completely replaced by tumour or 
the afferent lymph tract is blocked by extensive lymphatic tract infiltration, 
initial lymphoscintigraphy can fail to show any hotspot. Additional tracer 
injection under these circumstances might result in secondary scan failure, in 
which case ALND is mandatory. 
Lymphatic tumour burden does not seem to affect blue dye uptake 
because, in contrast to the uptake of radiocolloid, which is based on sufficient 
functional lymph tissue, blue dye uptake is a process of passive diffusion 
through the lymphatic system11. 
Massive nodal tumour and/or lymphatic tract infiltration was present in 
57.1 % of 14 patients (group A) early in our study, in which a negative initial 
lymphoscintigraphy was not followed by additional tracer injection, and in 
60% of 5 patients (group B), in which additional tracer injection, after initial 
scan failure, did not result in secondary SN visualization. 
If additional tracer injection does result in secondary SN visualization, as 
was seen in 33 patients (group C) in our study, it can be argued whether this 
visualized hotspot in fact is the true SN, or might be an alternative lymph node 
which, based on rerouting of lymph flow, is erroneously considered to be the 
true SN13'15,16. 
If so, rerouting of lymph flow during lymphatic mapping would ultimately 
result in increased false-negative rates17. 
However, in 33 patients with secondary SN visualization resulting from 
additional tracer injection, only one patient (5.5%) had a false-negative SN 
biopsy, whereas 15 patients with a negative SN after additional tracer injection, 
who consequently had no ALND, showed no axillary recurrences within 29 
months of follow up. These results suggest that SN biopsy after additional tracer 
injection does not compromise its accuracy, as was also pointed out by 
others18. 
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Internal mammary (IM) basin drainage 
The incidence of IM metastasis is correlated with axillary nodal involvement19. 
It seems intuitive, that a large axillary tumour burden can result in blockage of 
lymph flow to the axilla, consequently leading to re-direction of lymph flow to 
the IM-chain13. However our results, like those of other investigators11, show 
that extensive nodal infiltration of the axilla is not correlated with increased 
lymph drainage to the IM lymph nodes, since IM hotspots were noted in only 
5.4% (5/93) of patients with initial scan failure, versus 21.2% in patients with a 
successful initial lymphoscintigraphy (Table 1). This seemingly unexpected 
result is probably explained by the fact that patients with initial scan failure had 
a significantly increased mean age and BMI, whereby both factors are inversely 
correlated to IM lymph drainage. 
Palpable lymph nodes 
An axillary lymph node with gross tumour involvement, might consequently be 
enlarged, thus is more likely be detected by routine physical examination 
and/or axillary ultrasound. 
However, because a tumour-loaded lymph node also can be the same size as 
a tumour-negative lymph node, physical examination of the axillary lymph nodes 
in order to detect nodal metastases, has shown to be inaccurate20,21. Lymph nodes 
that can be palpated intraoperatively through the incision of the SN biopsy and are 
felt to be suspicious, should be harvested and regarded as SN2,22,2i. 
Axillary ultrasound 
Routine preoperative axillary ultrasound is advocated by several investigators 
[j,2o,24_ Combined with ultrasound-guided FNA of enlarged or suspicious lymph 
nodes, preoperative ultrasound can detect metastatic disease, hence avoiding 
an unnecessary or potentially unsuccessful SN biopsy. 
In this study, routine preoperative ultrasonography of the axilla, which was 
introduced in our institute in 2002, was performed in only 43 of the 93 patients 
with initial scan failure. Moreover, of 48 patients with a tumour-positive axilla 
in this subgroup, only 15 patients had a preoperative ultrasound examination of 
the axilla. In one of these patients, ultrasound showed a suspicious lymph 
node, which was tumour-negative on FNA. Among 15 patients, who showed 
extensive nodal involvement or extra nodal tract invasion in relation to initial 
scan failure (Table 2), preoperative axillary ultrasound was performed in only 
two patients. 
Thus, within this study we were not able to define the diagnostic yield of 
preoperative axillary ultrasound in relation to initial scan failure. 
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However, in retrospect, it seems clear, that a substantial number of our patients 
with initial scan failure would not have needed a lymphatic mapping procedure, 
had routine preoperative axillary ultrasonography been introduced earlier in our 
institute. 
Increased age 
With the loss of oestrogen levels in postmenopausal women, the breast 
parenchyma is partially replaced by fatty tissue. This process of fatty 
degeneration results in a substantial decrease of lymphatic capillaries, normally 
confined to the breast parenchyma, which in turn is correlated with decreased 
radioactive uptake in the SN. Thus, increased age is inversely correlated with 
the ability to visualize axillary hotspots and internal mammary hotspots13,25~29. 
Likewise, our study showed that the mean age of patients with initial scan 
failure was significantly higher when compared to patients with a successful 
initial lymphoscintigraphy. (65.8 ys versus 58.5 ys, p < 0.0001). 
The inverse effect of increased age on the technical success rate of 
lymphoscintigraphy becomes even more obvious when looking at the results of 
41 patients (group D) in our study with initial scan failure showing only very 
faint hotspots (Figure 3), necessitating additional tracer injection for successful 
SN retrieval. In this subgroup, in which massive nodal tumour infiltration as a 
causal factor was nearly absent (one patient), the mean age was 67 years, besides 
BMI accounting for the main factor to result in initial scan failure (Table 2). 
Body Mass Index (BMI) 
BMI is also recognized as a factor that affects the lymphoscintigraphic 
visualization of sentinel nodes26,27,30. As is true for increased age, patients with 
a high BMI might have sparse lymphatic capillaries and more fatty tissue in 
their breast parenchyma. 
In our study, the mean BMI was 29.0 for the patients with initial scan 
failure and 25.5 for a random sample of 100 patients with clearly visible 
hotspots on the initial scan. 
The difference was highly significant (P<0.0001). 
This result confirms the findings from other investigators regarding the 
effect of BMI on the success rate of lymphoscintigraphy. 
Previous excisional biopsy 
Previous excisional biopsy is reported to result in changing of lymphatic 
drainage patterns and scan failure4,13,31,32. In a previous study, we reported the 
results of 88 patients, in which SN biopsy with completion ALND was 
32 
Additional tracer improves SN identification rate 
performed following previous excisional biopsy33. Initial scan failure was seen 
in only 4 patients (4.5%) and no false-negative SN procedures were noted. In 
the present study 199 patients had a previous excisional biopsy. Of these, 8.0% 
showed initial scan failure as compared to 7.6% in patients, in which breast 
cancer was diagnosed by core biopsy (Tablel). Therefore, in our opinion, 
excisional biopsy prior to SN biopsy is not correlated with scan failure. 
CONCLUS ION 
Sentinel node (SN) biopsy has become the standard of care in the treatment of 
breast cancer. To prevent unnecessary ALND, the results of preoperative 
lymphoscintigraphy should be optimal. To avoid technical failure of lymphatic 
mapping, we evaluated the results and accuracy of additional intracutaneous 
radiocolloid tracer injections of 37 MBq (ImCi) in patients with initial scan 
failure. A negative initial lymphoscintigraphy, if followed by additional tracer 
injection, resulted in secondary SN visualization in 87% of these patients, thus 
enabling an accurate (false-negative rate 5.5%) SN biopsy. Both age and 
extensive nodal tumour infiltration as well as BMI adversely affect SN 
visualization. 
In case additional tracer injection does not result in (secondary) SN 
visualization, ALND is mandatory, because of the high risk of positive lymph 
nodes, many times with massive tumour infiltration of the axilla. 
If initial SN visualization is faint, this is mainly correlated with increased 
age and high BMI, rather than a large tumour burden. In these patients 
additional tracer injection facilitates an accurate SN procedure. 
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ABSTRACT 
Background 
Sentinel lymph node (SN) biopsy has been validated in the treatment of breast 
carcinoma and is considered to stage the axilla adequately in this disease. 
However, patients with previous excisional biopsy are regarded not eligible for 
SN biopsy. W e evaluated the results of SN biopsy for this group of patients 
based on confirmatory axillary lymph node dissection. 
Patients and methods 
As of April 1997 all consecutive patients with stage T ^ breast cancer were 
enrolled into a prospective study on SN biopsy. As part of this study, a total of 
88 patients, who had previously undergone diagnostic excisional biopsy 
followed by complete axillary lymph node dissection, were reviewed to 
determine the validity of the sentinel node procedure. 
Results 
Lymphoscintigraphy visualized one or more axillary hot spots in 84/88 patients. 
A successful SN biopsy was performed in 87 patients. Complete axillary lymph-
node dissection showed no false-negative SN biopsy among the 87 SN 
procedures. 
Conclusion 
SN biopsy is a reliable and safe method following excisional biopsy as is 
confirmed by completion axillary lymph node dissection. Therefore, patients 
with previous excisional biopsy are eligible for sentinel node procedure and 
can be spared unnecessary axillary lymph node dissection. 
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INTRODUCTION 
In the last decade sentinel node (SN) biopsy was introduced as a new 
technique for nodal staging in breast cancer1,2,3. As compared to axillary lymph 
node dissection (ALND), it provides similar staging information, yet with the 
advantage of generating only minimal morbidity. When performed by an 
experienced surgeon, sensitivity of SN biopsy is in excess of gso/o4'5'6'7'8-9'10. 
Therefore, a negative SN biopsy accurately predicts the absence of nodal 
tumour involvement in the axilla and justifies avoidance of complete ALND. 
However, controversy persists about the accuracy of SN biopsy following 
previous excisional biopsy. It is assumed that the lymphatic drainage pattern is 
altered in these patients, resulting in less accurate lymphatic mapping and 
unreliable results of the SN biopsy3,11. If this hypothesis is correct, then a 
number of breast cancer patients will be deprived of the advantages of the SN 
technique. 
To date there are no published validation studies in which the reliability of 
the SN procedure in breast cancer patients following previous diagnostic 
excisional biopsy is investigated by performing a completion axillary lymph 
node dissection. For this study we reviewed the relevant data in our large 
prospective database on SN biopsy, to determine the accuracy of the procedure 
in this selected group of patients. 
PATIENTS AND METHODS 
From an ongoing prospective study on SN biopsy we analysed all consecutive 
patients with stage T ^ breast cancer, who had undergone diagnostic excisional 
biopsy prior to SN biopsy (group A). In this group a total of 88 patients were 
operated in a period from April 1997 until January 2000. After having received 
approval of the local ethical committee and after obtaining informed consent, 
all group A patients underwent SN biopsy followed by a completion axillary 
lymph node dissection. All operative procedures were performed by two 
surgeons experienced in SN biopsies. In the same time period a total number of 
49 patients (group B) underwent SN biopsy and completion ALND following 
diagnostic core biopsy. This group was used for comparison. 
The lymphatic mapping procedure in both groups consisted of a dual-
tracer technique. The day before surgery, at the Department of Nuclear 
Medicine, a radioactive tracer was injected peritumorally (group B) or into the 
breast tissue adjacent to the biopsy cavity (group A), carefully avoiding injection 
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into the biopsy cavity itself. All patients received lOmCi (370 MBq) 99m 
Technetium nanocolloid (Nanocoll, Nycomed Amersham Sorin, Saluggia, Italy) 
in 4 ml saline. Lymphoscintigraphic images were obtained the next day, after a 
mean period of 16 hours after tracer injection, in three standard projections: an 
anterior and anterolateral view (arm in 90 degrees abduction) and a lateral view 
(arm raised above the head). Focal accumulation of radioactivity was registered 
as the localization, number and intensity of "hot spots" in and outside the axilla. 
The position of axillary and non-axillary SNs was marked on the skin 
preoperatively, with the help of a gamma camera and a hand-held gamma 
probe. In the operating room, shortly after induction of general anaesthesia, a 
dye tracer (0.8-1 ml Patent Blue V, Laboratoire Guerbet, Aulnay-sous -Bois, 
France) was injected intradermally in the skin above the tumour (group B) or in 
the skin surrounding the excisional biopsy scar (group A). 
During surgery, in all patients, attempts were made to harvest both axillary 
and non-axillary SNs, as visualized by lymphoscintigraphy. Intraoperative 
identification of the SNs was based both on blue dye mapping and gamma 
probe detection. A SN was defined as any node that was hot and/or blue. The 
SN procedure aimed at complete removal of all axillary SNs, as was confirmed 
by a reduction of background activity in the remaining axillary tissue to less 
then 10% of the ex vivo activity of the most active SN (ex vivo ratio 10:1). 
Completion axillary lymph node dissection involved at least removal of all level 
I and II lymph nodes. 
Histopathologic examination of the SN consisted of routine serial 
sectioning with hematoxylin and eosin (H&E) staining, followed by 
immunohistochemical (IHC) staining, whenever routine H&E staining did not 
reveal metastases. 
In relation to the mapping procedure, radiation exposure guidelines and 
doses were considered for both patients and personnel and were found to be 
well within legal safety limits, as was published previously12. 
RESULTS 
In all, 88 consecutive patients with previous excisional biopsy (group A) were 
included in this study. Patient characteristics are listed in Table 1. Tumour size 
was pT1 in 58 patients, pT2 in 27 patients and pT, in 3 patients. The average 
tumour size was 15 mm (range 3-70 mm). The primary tumour was located in 
the lateral quadrants in 55 patients, of which 26 tumours were in the upper-
outer quadrant. 
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Table 1 Patient characteristics of the excisional biopsy group (A) and the core biopsy group (B) 
Number of patients 88 49 
Mean age (y) 56 64 
Range _ _ _ 36-80 __ ___ jS9-94_ 
Tumour localization 
Lateral 55 28 
Medial 27 19 
Central _6_ 2 
Tumour size (mm) 
T, 58 11 
T2 27 32 
T3 3 6 
Mean 15 28 
Range _ 3-70 10-60 
Histology 
Ductal carcinoma 55 34 
Lobular carcinoma 16 8 
Ductal/lobular carcinoma 6 6 
Other 11 1 
Table 2 Results of lymphoscintigraphy for the excisional biopsy group (A) and the core biopsy 
group (B) 
A B 
Number of patients 88 49 
Axillary hotspots 84 47 
Axillary SN biopsy 87 49 
ALND 88 49 
Axillary metastases 35 20 
False negative SN 0 1 
IM hotspots 24 22 
IM SN biopsy 17 13 
IM metastases 5 2 
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\ 
Lymphoscintigraphy visualized one or more axillary hot spots in 84/88 
(Table 2). A successful SN biopsy was performed in all of these patients 
patients no visible SNs were seen on the lymphoscintigraphy images. | ' 
of these a SN could still be identified during operation by using the 
mapping technique, following a blue lymphatic duct leading to a blu^ ' 
SN. Overall successful axillary SN identification therefore was 
87/88 patients. ' ' 
In the remaining patient, who underwent previous excisional bj 
two different locations in the same breast, none of the two techniques v »J 
to identify a sentinel node. A complete axillary lymph node dissect,^ 
performed in this patient, revealing two metastatic nodes within a basj^ 
lymph nodes. 
In 68 patients the removed axillary nodes were both blue-stained 
In 16 patients the SNs could be localized only by the radiocolloid ^^ 
patients only by the blue tracer, as was mentioned. The median ex vivo 5 
ratio (ex vivo SN activity against background) of the axillary SNs was 2$ 
The mean interval between the previous excisional biopsy 
sentinel node procedure was 19 days (range 10-85). A median of 2 axil|a 
(range 1-12) per patient was removed. 
Following SN biopsy, all group A patients underwent complete a 
lymph node dissection. A median of 16 lymph nodes (range 4-32) was rgj 
during ALND (inclusive of the number of removed SNs). Overall a 
metastatic involvement was found in 35 patients. Axillary SN biopsy ca 
predicted the positive nodal status of the axilla in 34/35 patients. As ment 
in one axillary node-positive patient, SN identification was not succ 
There was no false-negative SN biopsy among the 87 successful SN proce 
Consequently, the sensitivity of SN biopsy following previous excisional 
in this study was 100%. The SN was the only involved axillary node 
patients with axillary metastases. 
Non-axillary SNs were seen predominantly in the internal mar 
nodal basin, in ail cases concomitant with axillary SNs. Lymphoscinti; 
showed additional internal mammary SNs (IM-SN) in 24 patients. Atten 
harvest these IM-SNs were successful in 17 patients. Metatastatic 
involvement of the IM-SNs was seen in 5 patients, in all cases in comb* 
with a tumour-positive axilla (Table 2). 
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DISCUSS ION 
Because of its high sensitivity and its minimally invasive nature, SN biopsy has 
replaced ALND as the primary procedure for axillary staging in breast cancer in 
many centers. However, various exclusion criteria have been formulated by 
different investigators. One of these exclusion criteria is a previous excisionai 
biopsy3,6,13. Prior surgery is assumed to alter the lymphatic drainage patterns by 
disrupting the lymphatic channels, thus preventing the surgeon from performing 
accurate lymphatic mapping and SN biopsy. Estourgie for example, by using 
repeated lymphoscintigraphy before and after excisionai biopsy in a group of 
20 breast cancer patients, found post-excisional differences in lymph drainage 
in 45% of patients with axillary drainage and in 80% of patients with internal 
mammary drainage, suggesting that SN biopsy is not valid when performed 
after previous excisionai biopsy14. 
However, although in recent years ultrasound-guided and stereotactic 
core biopsy have emerged as a more efficient alternative preoperative 
techniques in diagnosing invasive breast cancer in both palpable and non-
palpable breast lesions, diagnostic excisionai biopsy remains necessary in those 
cases in which core biopsy is inconclusive. Inconclusive core biopsy will be 
more frequent in patients with early-stage breast cancer and moreover, in these 
patients the likelihood of nodal involvement is low. Thus, by excluding patients 
with previous excisionai biopsy for SN staging on the assumption of 
unreliability, a substantial number of presumably node negative early-stage 
breast cancer patients, i.e. those who would benefit most from a SN biopsy, will 
be denied the advantages of the SN technique. 
Investigators, who do not exclude previous excisionai biopsy in their 
studies, monitor their accuracy of SN biopsy by determining the incidence of 
axillary relapse at follow up, since confirmatory axillary dissection usually is no 
longer performed routinely. Recently, such a large study was published 
concerning 543 patients who had undergone an open breast biopsy before SN 
biopsy. After a median follow-up of two years 3 nodal recurrences were 
observed in 383 SN negative patients15. These results confirm, without 
completion ALND, the accuracy of the SN procedure after prior breast surgery. 
The best way, however, to validate the accuracy of SN biopsy following 
previous breast surgery is to study the results of prospective studies comparing 
SN biopsy with the results of routine completion axillary dissection. After 
searching the literature we found no relevant studies. In our analysis of 88 such 
patients, we found no false negative results in 87 successful SN procedures, 
resulting in both a sensitivity and an accuracy of 100%. 
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Assuming there is a single lymphatic trunk that conveys lymph from the 
subareolar plexus toward the axillary lymph nodes16"18, large excisional 
biopsies in the upper lateral quadrant of the breast might distort this main 
lymphatic trunk, making the procedure less accurate. We, however, did not find 
such an influence in this relatively small subgroup of 26 patients with previous 
open biopsy in the upper outer quadrant. This might be explained by a 
relatively small tissue volume of the excisional biopsy, but this was not 
measured routinely in our series. 
We compared our findings in patients with previous excisional biopsy 
(group A) with 49 patients in which SN biopsy was performed after diagnostic 
core biopsy (group B). These patients, as for group A, were also operated in our 
learning phase, and therefore underwent a confirmatory ALND too. Patient 
characteristics of both groups are shown in Table 1. T1 tumours were more 
frequent in the previous excisional biopsy group, as can be expected, since 
small tumour size more often will result in inconclusive core biopsy. 
Lymphoscintigraphy showed axillary hotspots in 47/49 patients in group B, 
compared to 84/88 patients in group A. SN biopsy was successful in all patients 
in group B, but completion ALND revealed one false negative SN procedure 
after core biopsy (sensitivity 95%), compared to a sensitivity of 100% in the 
excisional biopsy group (Table 2). These comparable results support our 
opinion that previous excisional biopsy does not decrease the accuracy of the 
SN procedure. 
Prior breast surgery also might disrupt lymph drainage patterns to the 
internal mammary nodal basin. In comparing both groups, more IM hotspots 
were visualized in group B as compared to group A (45% versus 27%) (Table 
2). However, after re-evaluating our previously published data on IM SN biopsy, 
in which 256 patients with both diagnostic core biopsy (160 patients) and 
excisional biopsy (96 patients) were included19, no differences between both 
groups are found: IM SN's were successfully imaged by lymphoscintigraphy in 
26% in patients with diagnostic core biopsy, compared to 25% in the previous 
excisional biopsy group. The IM-SN identification rate in the core biopsy group 
was 59%, patients with previous excisional biopsy showed identification rates 
of 71%. These data demonstrate that previous excisional biopsy neither affects 
the visualization nor the identification of internal mammary sentinel nodes. 
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CONCLUS ION 
Sentinel node biopsy for breast cancer following previous excisional biopsy is 
accurate for axillary lymph node staging, as is confirmed by completion axillary 
lymph node dissection in this study. Localisation of the biopsy, even in the 
upper outer quadrant, does not affect identification of the axillary sentinel 
node. Moreover, visualization and identification of internal mammary sentinel 
nodes is not impaired. Therefore, patients with previous excisional biopsy are 
eligible for the sentinel node procedure and can be spared an unnecessary 
axillary lymph node dissection. 
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Incidence of axillary recurrence in 
344 sentinel node negative breast 
cancer patients after intermediate 
follow-up 
A prospective study into the accuracy of sentinel node 
biopsy in breast cancer patients 
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ABSTRACT 
Sentinel lymph node biopsy (SLNB) has been validated in the treatment of 
breast carcinoma and is considered to stage the axilla adequately in this 
disease. However, long term follow-up data are only scarcely available. W e 
evaluated the results of SLNB with respect to locoregional failures in the axilla 
in SN-negative patients with invasive breast carcinoma and analysed their 
causal factors. 
Between 1997 and May 2004, 656 patients without clinically palpable 
lymph nodes entered our study. Data with regard to demographics, diagnostics, 
therapy and follow up were gathered prospectively from all patients. Patients 
treated after May 2004 were excluded from this study to permit at least one year 
of follow-up. 
Out of the 656 patients, 344 patients with a negative sentinel lymph node 
biopsy did not undergo axillary dissection and were followed up clinically. 
Median follow up was 43 months. In 3 patients (0.9%) axillary recurrences 
developed. All three patients subsequently underwent a completion axillary 
dissection, chemotherapy and radiotherapy. 
The low rate of clinical axillary recurrence after an intermediate follow up 
period suggests that a negative SN biopsy accurately reflects the nodal stage in 
patients with breast cancer. 
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INTRODUCTION 
For decades axillary lymph node dissection (ALND) has been part of the standard 
procedure in surgical treatment of breast cancer. Axillary lymph node status, as the 
most important prognostic indicator for recurrence and survival and determinant 
for subsequent adjuvant therapy, is still an essential element in the treatment of 
breast cancer1,2. Since the introduction of the sentinel lymph node biopsy (SLNB) 
as a new technique for nodal staging in breast cancer it has evolved to a generally 
accepted procedure1,4. As compared to ALND, SN biopsy causes less morbidity 
and is considered to provide the same staging information. When performed by an 
experienced surgeon, it has shown to be reliable5,6 as based on validation studies 
that determined the accuracy of the SN in predicting the status of the remaining 
axillary lymph nodes in a "back-up" ALND. However, little is known regarding 
intermediate follow-up results and no long-term data are currently available. 
In the present prospective study we describe our results of the follow-up of 
sentinel node negative patients who did not receive elective ALND. Special 
attention was paid to axillary recurrence and possible reasons for this relapse. 
MATERIALS AND METHODS 
As of 1998, after validation of the sentinel node technique in our institute by 
performing confirmatory ALND in 138 patients (false negative rate 2%, sensitivity 
98%), completion axillary lymph node dissection was omitted in case of a 
negative SLNB. Subsequently, from July 1998 until May 2004, 656 consecutive 
patients with clinically node-negative operable primary breast cancer, who 
underwent SLNB, entered a prospective database. Exclusion criteria included 
pregnancy and T4 tumours. To allow at least one year of potential follow-up, 
patients treated after May 2004 were excluded from this analysis. At least one 
sentinel node (SN) could be identified in 639 out of 656 patients (97,4%). In the 
remaining 17 patients no SN could be identified and a primary axillary clearance 
was performed. In 344 of 639 patients, the sentinel lymph node did not reveal 
metastases. Of these 344 patients, diagnosis of invasive breast cancer was obtained 
by core needle biopsy in 288 (84%) and by excisional biopsy in 56 (16%) patients. 
Our technique of SN biopsy has previously been described in detail7. The 
lymphatic mapping procedure consisted of a dual-tracer technique. All patients 
received peritumoural injection of 10mCi (370 MBq) t)t)m Technetium 
nanocolloid (Nanocoll, Nycomed Amersham Sorin, Saluggia, Italy) in 4 ml 
saline. Lymphoscintigraphic images were obtained in all patients. Additionally, 
0,8-1 ml Patent Blue V. 
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(Laboratoire Guerbet, Aulnay-sous-Bois, France) was injected intradermally 
above the tumour or alongside the excisional biopsy scar. During surgery in all 
patients attempts were made to harvest both axillary and non-axillary SNs, as 
visualized by lymphoscintigraphy. 
Histopathologic examination consisted of routine haematoxylin and eosin 
(H&E) staining and serial sectioning, followed by immunohistochemical staining 
whenever routine H&E staining did not reveal metastases. Micrometastases were 
defined based on a size greater than 0.2 mm and less than or equal to 2 mm in 
diameter according to the Dutch national guidelines. Patients with solitary 
tumour cells in the sentinel node (equal to or smaller than 0.2 mm) were 
considered to be node-negative. 
After breast conserving surgery patients received post-operative adjuvant 
radiation therapy with 50 Gy for the whole breast in 5 weeks with an additional 
boost of 16 Gy to the tumour site for patients under the age of 60 years. No 
radiation was given to the axilla. SN negative patients received adjuvant 
systemic treatment according to the Dutch national guidelines within the study 
period, as described in Table 1. 
All patients were seen for follow up every 3 months during the first year 
Table 1 Adjuvant systemic treatment regimens for SN negative breast cancer patients, guidelines 
1999-2003. 
•Starting 2003 all patients <35 years received adjuvant therapy independent of tumour 
characteristics. 
**Adjuvant treatment: -ER-/PR- patients receive chemotherapy without hormonal therapy 
-Patients <60 yrs and ER/PR+ receive chemotherapy in combination with hormonal therapy 
-Patients 60-70 yrs and ER/PR+ receive hormonal therapy and chemotherapy based on patient and 
tumour characteristics. 
***Grade III and ER/PR+ : adjuvant hormonal therapy 
****ER/PR+ hormonal therapy, ER/PR-: consider chemotherapy 
Tumour size <1cm 1-3 cm >3cm 
Premenopausal * No No Yes** 
Gr l/ll 
Grill No Yes** Yes** 
Postmenopausal No No 
Yes** 
Gr l/ll 
Grill No Yes** Yes** 
>70 years No No*** Yes**** 
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and every 6 months in the second year following surgery. Thereafter follow up 
was once a year. Follow up consisted of physical examination and a yearly 
bilateral or contralateral mammography. Special attention was paid to axillary 
and locoregional recurrence by clinical examination only. No screening tests 
were carried out to exclude the presence of distant metastases. 
RESULTS 
Patient and tumour characteristics are listed in Table 2. All 344 patients without 
metastases were included in the study. 
Preoperative lymphoscintigraphy was performed in all patients and 
axillary hotspots were visualised in 343 patients. In one patient no visible SNs 
were seen on the lymphoscintigraphy images. A sentinel lymph node could 
still be identified during operation by using the blue dye mapping technique. 
Additional lymph drainage to the internal mammary nodes was seen in 53 of 
the 343 patients (15%). Axillary sentinel nodes were identified and removed in 
all cases. The mean number of axillary sentinel nodes removed was 2.1 (range 
1-7). Internal mammary SNs were harvested in 34 (64%) of relevant patients. 
After a median follow-up of 43 months (mean 45 months, range 1-7 years) 
three axillary relapses occurred. The first patient, aged 52 years was found to 
have an axillary recurrence 21 months after the initial sentinel node procedure. 
A core biopsy was performed in 2000 in this patient and a grade 2 invasive 
ductal carcinoma with a diameter of 22 mm was diagnosed. A standard SN 
procedure was performed according to our protocol as described above. 
Preoperative lymphoscintigraphy showed one axillary and one internal 
mammary sentinel node, both of which were removed. Histopathologic 
analysis, including immunohistochemistry, did not reveal metastases. During 
the SN procedure, a palpable radioactive lymph node was found in the axilla, 
which was not stained with blue dye. Against protocol this node was judged not 
to be a sentinel lymph node and was left behind. After secondary removal of 
this (the same?) node under local anaesthesia pathological examination 
revealed no metastases. In January 2002, following the development of an 
axillary recurrence, a complete axillary lymph node dissection was performed. 
In 7 of the 8 lymph nodes resected, metastases were detected. Locoregional 
radiotherapy, chemotherapy and hormonal therapy was started. At present, the 
disease is stable using an aromatase inhibitor. 
A second patient, aged 61 years, developed an axillary relapse after a 
follow up of 17 months. Her medical history mentioned bilateral breast 
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reduction surgery in 1985. In August 2000 an excisional biopsy was performed 
and revealed a grade 3 ductal carcinoma with a diameter of 31 mm. Lymphatic 
mapping showed an axillary and a parasternal hotspot. Two axillary sentinel 
nodes were identified and removed, but the internal mammary sentinel node 
could not be harvested due to its subcostal localisation. Although the axillary 
sentinel nodes did not contain any metastases, axillary recurrence was 
confirmed in February 2002 and an axillary lymph node dissection revealed 6 
positive lymph nodes, of which two with extracapsular extension, in the axillary 
basin which contained 22 lymph nodes in all. She received chemotherapy and 
radiotherapy, but died in 2003 from disseminated disease. 
The third patient, 49 years old, developed an axillary recurrence 26 
months after initial breast surgery for a grade 2 ductal carcinoma, 12 mm in 
diameter. Lymphoscintigraphic images showed, besides 4 axillary hotspots, 
accessory flow towards one infraclavicular node. All axillary and the 
Table 2 Clinical and pathological characteristics of the study population 
SN- (344 patients) SN+ (295 patients) 
Mean Age (yr) 65.8 60.6 
Tumour size 
Diameter <20 mm 218(63.4%) 115(39.0%) 
20-49 mm 121(35.2%) 149(50.5%) 
>49 mm 5(1.5%) 31(10.5%) 
Tumour histology 
Ductal 254(73.8%) 215(72.9%) 
Lobular 57(16.6%) 71(24.1%) 
Other 33(9.6%) 9(3.0%) 
Grading 
I 124(36.0%) 62(21.0%) 
II 133(38.7%) 131(44.4%) 
III 87(25.3%) 102(34.6%) 
Left/right 179/165 168/127 
Breast quadrant 
Upper-outer 162(47%) 166(56%) 
Upper-inner 80(23%) 39(13%) 
Lower-outer 42(12%) 31(11%) 
Lower-inner 32(9%) 23(8%) 
Central/Paget 28(8%) 36(12%) 
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infraclavicular sentinel nodes were removed, but these were all negative for 
metastases. A completion ALND after the diagnosis of the axillary relapse 
contained 12 nodes, of which 2 contained metastases. She received hormonal 
therapy, but later on she was diagnosed with pulmonary metastases. Since then 
metastatic disease has been stable under aromatase inhibitors. 
DISCUSS ION 
Screening mammography has led to the detection of breast cancer at an earlier 
stage and consequently more women are diagnosed with breast cancer without 
axillary lymph node involvement. For this group of patients, routine performance 
of an axillary clearance induces substantial additional morbidity, but is not 
beneficial. Nowadays ALND is abandoned in case of a negative SN biopsy and 
many women are spared the morbidity of ALND. Although the short-term 
accuracy of the SN technique has been described repeatedly, it remains 
important to evaluate long-term follow-up results as well, especially with 
respect to axillary relapse as an indicator of a false-negative SN procedure. 
Axillary recurrence rates after complete ALND range from 0% to 2%a"10. 
Subsequently, negative SN biopsy without axillary clearance should at least 
achieve similar results regarding axillary relapse. Axillary recurrences will be 
clinically manifest within two years after initial surgery in 75% of relevant 
patients'1. Table III summarizes the results of published studies which have 
investigated axillary recurrence after negative SN biopsy, showing axillary 
relapse ranging from 0% to 1.5%1l" i5. The median follow-up reported was 14 
to 57 months. Our own results, with an axillary recurrence rate of 0,9% after a 
median follow up of 43 months, support the conclusion of these studies 
regarding axillary recurrence following negative SN biopsy without ALND: SN 
biopsy indeed is a reliable procedure to determine the nodal status in breast 
cancer patients without the morbidity of conventional ALND. 
To reduce the chances of a false negative SN biopsy in the future, we 
reviewed the 3 patients with an axillary relapse in our series. The first patient 
was found to have a palpable axillary lymph node during SN biopsy. One of the 
known pitfalls of the SN procedure is massive tumour infiltration of the primary 
draining lymph node and subsequent rerouting, thereby labelling another 
lymph node as SN, thus failing to identify the true SN which contains 
metastases. These lymph nodes can frequently be detected clinically, by 
preoperative ultrasound or during surgery. Nowadays, we routinely perform an 
ultrasonographic investigation of the axilla with a fine needle aspiration in case 
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of a palpable lymph node or an abnormal lymph node at ultrasound. Hence, 
patients with increased risk of labelling a false SN can be excluded. 
Additionally, every palpable lymph node, found in the axilla during surgery, 
should be regarded as a potential sentinel lymph node and therefore should be 
removed, independent of radioactivity or blue staining9. 
The second patient with an axillary recurrence had a history of major prior 
breast surgery, i.e. bilateral breast reduction surgery. Moreover, in this patient 
SN biopsy was preceded by a diagnostic excisional biopsy. 
As yet, there has been no consensus regarding the accuracy of SN biopsy 
following prior breast surgery. Several investigators reported that patients with 
previous excisional biopsy are not eligible for SN biopsy4,6,36, because prior 
surgery is assumed to alter the lymphatic drainage patterns by disrupting the 
lymphatic channels. Recently, we published a validation study in 88 patients 
with previous excisional biopsy, in which SN biopsy proved to be highly 
accurate, as confirmed by completion ALND (sensitivity 100%)37. Also, a large 
observational study was published concerning this group of patients, in which, 
after a median follow-up of two years, four nodal recurrences were observed in 
543 patients38. Both studies confirm the accuracy of the SN procedure 
following prior excisional biopsy. However, in breast reduction surgery, the 
anatomy of the subareolar region is altered substantially, which may well 
explain the false negative result in this patient. 
The third patient with an axillary relapse was found to have an 
infraclavicular hotspot on preoperative lymphoscintygraphy. Axillary and 
infraclavicular SN biopsy were found to be negative. In retrospective, we could 
not identify any reason for the false negative result in this patient. 
Based on a generally accepted false negative rate of the SN procedure of 
5%, Roumen et al. showed that the expected number of patients with residual 
axillary metastases is 3%12. Our own data, as well as that of the published 
series shown in Table III, found axillary recurrence to be less than expected. 
Although, in theory, this could be the result of a relatively short follow-up 
period, most published studies (Table 3) have a median follow up exceeding 
two years, as the period in which axillary relapse generally becomes manifest. 
Our own results showed axillary recurrence 26, 21 and 1 7 months after initial 
treatment. Another possible explanation for these low rates of axillary relapse is 
the scrupulous pathologic examination for (micro)metastases within the 
sentinel node procedure. Finally, the use of more effective adjuvant systemic 
therapy in many patients nowadays may result in remission or down staging of 
residual axillary metastases. This may even delay or prevent axillary recurrence 
to become clinically manifest. 
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Table 3 Axilllary recurrence after negative SN biopsy without ALND 
Author Year Patients Median follow up Axillary recurrence Axillary recurrence 
(months) after (months) 
Giuliano" 2000 67 39 0 
Roumen12 2001 100 24 1(1%) 14 
Schrenk13 2001 83 22 0 
Veronesi'4 2001 285 14 0 
Chung15 2002 208 26 3(1.4%) 4,11,40 
Meijer16 2002 100 47 1(1%) 24 
Hansen" 2002 238 39 0 
Loza18 2002 168 21 1(0.6%) 30 
Reitsamer19 2003 116 22 0 
Ponzone20 2003 150 15 0 
Blanchard2' 2003 685 29 1(0.1%) 41 
Badgwell22 2003 159 32 0 
Veronesi23 2003 167 46 0 
Jeruss24 2005 592 27 1(0.2%) 22 
Smidt25 2004 439 26 2(0.5%) 4,27 
Mark26 2004 2340 31 3(0.13%) 18, 29,38 
Langer27 2005 149 42 1(0.7%) 14 
Kokke28 2005 113 37 1(0.9%) 29 
Wessem29 2004 82 28 1(1.2%) 24 
Torrenga30 2004 104 57 1(1.0%) 24 
Veronesi31 2005 953 38 3(0.3%) 20,30,38 
Zavagno32 2005 479 36 0 
Sanjuàn33 2005 158 21 1(0.6%) 19 
Swenson34 2005 612 33 3(0.5%) 11,24,36 
De Kanter35 2006 149 65 4(2.6%) 10,12,14, 56 
Current study 2006 344 43 3(0.9%) 17,21,26 
C O N C L U S I O N 
Our results in this follow-up study indicate that adequate staging is achieved by 
SN biopsy in breast cancer patients. This procedure does not lead to an 
increased incidence of axillary recurrence, as compared to ALND. Although 
longer follow-up is required, these midterm follow-up data support the current 
opinion that ALND can be safely abandoned in case of a negative SN biopsy. 
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ABSTRACT 
Introduction 
Nowadays, axillary sentinel node (SN) biopsy is a standard procedure in the 
staging of breast cancer. Although the internal mammary (IM) lymph node 
status is a major i n d e p e n d e n t prognostic factor in breast cancer patients, 
sampling of IM sentinel nodes (IMSNs) is not performed routinely. The aim of 
this study was to determine the likelihood of finding IM lymph node metastases 
in case of IM hotspots on lymphoscintigraphy and evaluate the relevance of 
I MSN biopsy as a method to improve staging. 
Patients and methods 
Between April 1997 and May 2006, a total of 1008 consecutive patients with 
clinically node-negative operable primary breast cancer were enrolled in a 
prospective study on SN biopsy. Both axillary and IMSNs were sampled, based 
on lymphoscintigraphy, intraoperative gamma probe detection and blue dye 
mapping, using 10 mCi (370 MBq ) "mTc-nanocolloid injected peritumourally, 
and 0.5-1.0 ml Patent Blue V injected intradermally. 
Results 
Lymphoscintigraphy showed axillary sentinel nodes in 98% (989/1008) and 
IMSNs in 20% of the patients (1 96/1008). Sampling the IM basin, as based on 
the results of lymphoscintigraphy, was successful in 71% of the patients 
(139/196) and revealed metastases in 22% (31/139). In 29% percent of the 
patients with positive IMSN's (9/31) no axillary metastases were found. 
Conclusion 
Evaluation of IMSNs improves nodal staging in breast cancer. Patients with IM 
hotspots on lymphoscintigraphy have a substantial risk (22%.) of metastatic 
involvement of the IM chain. In addition, true IM node-negative patients can be 
spared the morbidity associated with adjuvant radiotherapy. 
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INTRODUCTION 
The sentinel lymph node (SN) procedure has become the standard of care for 
staging clinically node negative patients with breast cancer1"3. However, 
controversy exists about the management of extra-axillary nodes, especially 
those located in the internal mammary (IM) chain. 
In addition to the axillary lymph node status, the IM lymph node status 
provides important prognostic information in breast cancer patients4. If positive, 
prognosis is less favorable. However, when lymphatic mapping reveals IM 
drainage, staging of these nodes is not performed routinely, thus discarding 
additional staging information. 
Most authors do not perform IMSN biopsy, because the clinical 
importance of IM lymph node metastases is unclear. Results of ongoing trials 
are needed to formulate treatment guidelines for these patients. 
The aim of this study was to determine the risk of IM lymph node 
metastases in case of IM hotspots on lymphoscintigraphy and evaluate the 
relevance of IMSN biopsy as a method to improve staging, as based upon the 
results of a 9 years period, in which IMSN biopsy was performed on a routine 
basis in patients with primary breast cancer. 
PATIENTS AND METHODS 
From April 1997 until May 2006, having received approval of the local ethical 
committee, and having obtained informed consent, all consecutive patients 
with clinically node-negative operable primary breast cancer were included in 
a prospective study on SN biopsy. Except for pregnancy and T4-tumours, no 
patients were excluded. 
Sentinel node technique 
Our technique of SN biopsy involves the injection of 10 mCi (370 MBq) "mTc-
nanocolloid, the day before surgery in 3-4 depots around the tumour or in the 
breast parenchyma surrounding the cavity of a previous excisional biopsy5. In 
case of non-palpable tumours, the radiocolloid tracer was injected within the 
relevant quadrant of the breast, without the use of ultrasound guidance. 
Lymphoscintigraphy was performed on the next day, after a period of 16-18 hours 
following radiotracer injection, and shortly before surgery. Lymphoscintigraphic 
images were obtained in three standard positions: anterior, anterior oblique and 
lateral. The location of axillary and non-axillary SNs was marked on the skin. 
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After induction of general anaesthesia in the operating room, '10-15 minutes 
before the incision, 0.8-1.0 ml Patent Blue V (Laboratoire Guerbet, France) was 
injected intradermally above the tumour or alongside the scar of the excisional 
biopsy. During surgery in all patients attempts were made to harvest both axillary 
and non-axillary SNs, as visualized on lymphoscintigraphy. The IMN biopsy 
technique, described by Haagensen6, can usually be performed using the 
mastectomy incision. In breast conserving therapy a small additional horizontal 
incision (2.5- 3 cm) over the desired interspace was used to sample IMSNs. In 
case of multiple IM hotspots on the lymphoscintigraphy, the IM lymph nodes 
were mostly retrieved through the same incision. 
Intraoperative identification of the SNs was based both on blue dye 
mapping and gamma probe detection (1997: RMD 10 mm, Radiation 
Monitoring Devices USA, 2000: Navigator, Navigator gamma guidance system, 
Watertown, USA and 2006: Europrobe, EuroMedical Instruments Strasbourg, 
France). Interference from primary site radioactivity of medial tumours, 
impeding IMSN identification, was managed by using an additionally 
collimated gamma probe and by narrowing the energy window of the probe, 
which decreases the influence of scattered radiation from the primary injection 
site. A postoperative chest X-ray was made routinely following IM node biopsy, 
to exclude accidental pneumothorax. 
In Phase I of this study (137 patients) SN biopsy was followed by 
completion axillary lymph node dissection in all cases. In Phase ll, after 
validation of the SN technique in our institute, completion axillary lymph node 
dissection was performed only in cases of a tumour-positive axillary SN or non-
successful SN procedure. Histopathologic examination of the SNs consisted of 
routine hematoxylin and eosin (H&E) staining, followed by serial sectioning 
and immunohistochemical staining whenever routine H&E staining did not 
reveal metastases. 
Statistical analysis 
We analyzed three end-points: visualization of the IMSNs, successful biopsy of 
the IMSNs and the presence of IM lymph node metastases. We used Chi-square 
tests to compare patient groups with respect to age, tumour localization, tumour 
size, axillary nodal status, tumour grade and progesterone and estrogen receptor 
status. A multivariable logistic regression analysis was performed to determine the 
independent predictive effect of these covariates for each of the three end-points, 
using a backward stepwise selection of the co-variates. Co-variates were excluded 
from the model if the probability of the likelihood ratio statistic was larger than 
0.05. Only the results of the final multivariable model will be presented. 
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RESULTS 
General characteristics 
A total of 1008 consecutive patients with breast cancer were included in this 
study. All but three patients were women. Their mean age was 59 years (range: 
29-96). Preoperative diagnosis was documented by fine-needle aspiration or 
core biopsy in 823 patients and by previous excisional biopsy in 185 patients. 
Lymphoscintigraphy visualized axillary hot spots in 98% of the patients. The 
axillary SN biopsy was successful in 98%. The axillary basin was tumour-
positive in 42%. Of the 427 patients with positive axillary lymph nodes, 328 
had 1-3 positive nodes and 99 had >3 positive nodes. The mean number of 
positive axillary lymph nodes was 3.5 (range: 1-37). 
Visualization of IMSNs 
In 196 patients additional hot spots were noted in the IM chain. Exclusive 
drainage to the IM lymph nodes was absent in our series. In 185 patients with 
previous excisional biopsy, 45 patients had IM hotspots and in 823 patients 
with core biopsy, 151 patients showed IM hotspots (p=0.06). Of the 196 
patients with IM hotspots, 115 underwent a mastectomy, compared to 812 
patients without IM hotspots, of which 495 underwent ablative treatment 
(P=0.82). 
The proportion of patients in whom the IMSNs could be visualized 
decreased with age and was also smaller for patients with a tumour in the lateral 
part of the breast, compared to those with a tumour in the medial or central part 
of the breast (Table 1). No significant associations were observed with tumour 
size and grade, axillary nodal status and estrogen and progesterone receptor 
status. In the multivariable logistic regression analysis, age and tumour 
localization were the only independent predictors for the ability to visualize the 
IMSNs (PcO.OOD. 
Biopsy of IMSNs 
1MSN biopsy proved successful in 139 of the 196 of patients showing internal 
mammary hotspots on the scan. Failure in harvesting the IMSNs was mostly due 
to insufficient radioactivity uptake (n=32), followed by subcostal location of the 
SNs (n=13), a shine through effect (n=6), a pleural lesion (n=3) or a mediastinal 
location of the SNs. 
IMSNs were mostly found in the third interspace (36%), with 26%, 25% 
and 9% of IM hotspots in the second, fourth and fifth interspace respectively. 
In the 139 patients with a successful IMSN biopsy, the mean number of 
73 
Chapter 10 
Table 1 Comparison of characteristics of patients who had visualized internal mammary sentinel 
nodes (IMSN'si versus those who had no IMSN's visualized on preoperative lymphoscintigraphy 
(N=100Bi. 
Characteristic IM SN's not visualized IM SN's visualized P-value 
(N=812) (N=196) 
Age 
s50 202 95 <0.0001 
51-70 416 76 
>70 194 25 
Period of diagnosis 
1997-1999 182 61 0.03 
2000-2002 318 72 
2003-2006 312 63 
Tumour localization 
Lateral 468 73 <0.0001 
Medial 266 98 
Central 62 25 
Tumour size 
s20mm 449 114 0.68 
>20 mm 337 80 
AxMaty nodal status (pN) 
Negative 475 106 0.26 
Positive 337 90 
Tumour grade 
Good 200 54 0.61 
Moderate 342 76 
Poor 257 64 
Estrogen receptor status 
Negative 159 38 0.94 
Positive 594 144 
Progesterone receptor 
Negative 267 60 0.56 
Positive 486 121 
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removed SNs was 1.5 (range 1-5). Ninety patients had one IMSN removed, 32 
two nodes, 13 three nodes, 3 four nodes and one patient five nodes. 
In 10 IMSN procedures a small pleural lesion was noted intraoperatively. 
Recovery was uneventful following simple vacuum drainage in the first three 
patients and no additional treatment in the following patients. All patients were 
checked with chest X-rays to exclude development of a pneumothorax. No 
bleeding was encountered. 
The proportion of patients with a successful biopsy of the IMSNs 
decreased with age (Table 2). In the univariate analysis, none of the other 
factors were significantly associated with the likelihood of a successful biopsy 
of the IMSNs. In the multivariable logistic regression analysis age appeared to 
be a independent predictor for the success of the IMSN biopsy. The risk of 
failure of IMSN biopsy was almost five times higher for patients >70 compared 
to those of 50 years or younger (OR: 4.62, 95%CI: 1.74-12.27). The risk of an 
unsuccessful biopsy of the IMSN biopsy also tended to be lower for patients 
with a moderately or poorly differentiated tumour than for those with a well 
differentiated tumour (OR: 0.36, 95%CI: 0.15-0.89). Twelve of the 57 patients 
with an unsuccessful IMSN biopsy had a previous excisional biopsy, compared 
to 33 of the 139 patients with a successful biopsy (p=0.68). 
IM lymph node metastases 
IMSN biopsy revealed metastatic involvement in 31 of the 139 patients with a 
successful biopsy. Of these .31 patients 9 had a negative axillary SN biopsy (AX-
/IMN+) and 3 had micrometastases only. Of the patients with IM lymph node 
metastases 32% had a tumour in the lateral part of the breast, 58% in the medial 
part and 10% in the central part of the breast. Eleven of the 31 patients with 
positive IMSN's had only micrometastatic disease. Of the 31 IM-positive patients, 
5 had an excisional biopsy, compared to 28 of the 108 IM negative patients 
(p=0.26). In the univariate analysis, the chance of finding a positive IM lymph 
node was significantly higher for patients with a tumour >2 cm compared to those 
with a tumour of 2cm or less (P=0.01). The risk of finding a positive IM lymph 
node was also elevated for patients with a positive axillary lymph node status, as 
compared to those with a negative axillary nodal status. In the multivariable 
analysis of the total patient population, axillary lymph node status (OR: 3.40, 
95%CI: 1.45-7.97 for node-positive versus node-negative patients), tumour 
location (OR: 2.91, 95%CI: 1.33-6.36 for medially versus laterally located 
tumours) and age (OR: 0.41, 95%CI: 0.18-0.92 and OR: 0.19, 95%CI: 0.04-0.84 
for patients aged 51-70 and >70 years respectively, as compared to those aged 
<50 years) were independent predictors for IM lymph node metastases. 
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Table 1 Comparison of characteristics of patients with successful and unsuccessful biopsy of 
internal mammary sentinel nodes (IMSNs). Including only patients who had IMSNs visualized on 
preoperative lymphoscintigraphy (N = 196). 
Characteristic 
Age 
<50 
51-70 
_ >70 
Period of diagnosis 
1997-1999 
2000-2002 
2003-2005 
Tumour localization 
Lateral 
Medial 
Central 
Tumour size 
<20 mm 
>20 mm 
Axillary nodal status (pN) 
Negative 
Positive 
Tumour grade 
Good 
Moderate 
Poor 
Estrogen receptor status 
Negative 
Positive 
Progesterone receptor 
Negative 
Positive 
Unsuccessful biopsy 
of IMSNs 
(N=57j 
21 
23 
13 
22 
22 
13 
23 
26 
30 
27 
74 
65 
20 
19 
18 
11 
42 
20 
33 
Successful biopsy 
of IMSNs 
(N=139) 
74 
53 
12 
39 
50 
50 
50 
72 
17 
53 
32 
25_ 
34 
57 
_46 
27 
102 
40 
P-value 
0.01 
0.16 
0.73 
0.26 
0.71 
0.32 
0.98 
0.40 
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P I S C U S S I O N 
^ ^ n y studies on lymphatic drainage of the breast have confirmed the 
Importance of the IM basin as a second draining route in breast cancer 7;8. As 
a consequence, IM lymph node dissection was part of the standard surgical 
t r e a t m e n t in the 1950s and 1960s. This radical surgical procedure was 
a t » £ i n c ' o n e c ' ' n 1970s because patient outcome studies showed that radical 
j j s sec t i on did not improve survival. However, these studies have clearly shown 
t h a t patients with documented IM metastases, who did not receive adjuvant 
therapy , have a worse prognosis. As a consequence, IMSN biopsy can refine 
s t a g i n g in breast cancer patients and offers the possibility of providing tailor-
r p a d e treatment in case of proven metastases to the IM chain. 
1/vt hotspot visualization 
I n the present study, including more than 1000 breast cancer patients, IM 
hotspots were seen in 20% of the patients. This is largely in accordance with the 
f i gu r e s reported by other studies (Table 3), which range from 14 to 22%)9"13. 
Differences between studies in the proportion of patients with a successful 
visualization of the IM lymph nodes could be explained by differences in the site 
o f tracer injection and the particle size of the tracers. W e use a peritumoural 
in jec t ion technique, which is associated with a higher visualisation rate of IM 
hotspots as compared to superficial injection techniques'4. Differences between 
s tud ies could also be explained by differences in the age distribution of the patients 
a n d the location of their tumour. As reported by others, we found that IM lymph 
d ra inage was more common in younger women and in patients with medially 
l o c a t e d tumours9,10. The influence of tumour localization and age on the 
visualization of IMSN was confirmed in a multivariable analysis. IM visualization 
T a b l e 3 Published series concerning visualization and exploration of IMSNs in breast cancer 
p a t i e n t s 
A u t h o r Year Number of patients Visualization of IMSN (%) Successful biopsy of IMSN 
C u r r e n t study 2007 1008 20% 139/198 (70%) 
M a d s e n 1 0 2007 509 22% 85/109 (78%) 
Le iden ius 3 2006 984 14% 121/138(88%) 
Paredes 1 3 2005 323 17% 32/44 (73%) 
Fa r rus 1 2 2004 225 14% 14/20 (69%) 
E s t o u r g i e " 2003 681 22% 130/150 (87%) 
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is not influenced by different time intervals between radioactive tracer injection 
and lymphoscintigraphy i.e. between early and delayed imaging' 
IMSN successrate 
Although the success rate for harvesting SNs in the IM chain is lower than for 
axillary SNs, 70% of the visualized IM nodes were retrieved, which is 
comparable to other studies (Table 3)''"' l J 
Failure was mainly associated with insufficient radioactive uptake. 
However, since the introduction of SPECT-CT in 2006, it became clear that a 
substantial number of these vague hotspots are located in the mediastinum, and 
therefore beyond reach. 
Complications of IMSN biopsy 
As reported by others, we found that IMSN biopsy has few complications15,1''. 
Morbidity was limited as a result of the small incisions over the intercostal 
space, leading to good cosmetic results. Pleural lesions occurred in 10 patients, 
with uneventful recovery in all of them. We did not encounter any bleeding 
from the IM artery. 
IM metastases 
The overall risk of IM lymph node metastases in breast cancer patients is well 
known and reported to be 18-33%. Metastases exclusively situated in the IMN, 
without concurrent axillary metastases, occur in 2-11% of patients15. 
Important factors predicting the likelihood of IM lymph node metastases 
are the axillary nodal status, the localization and characteristics of the primary 
tumour and patients age4,6,17,1819. 
Our results also show that IM lymph node metastases are mostly found 
concomitantly with axillary metastases and are more common in larger 
tumours. In the multivariate analysis, a positive axillary lymph node status, 
medial tumour location and decreasing age were independent predictors for a 
positive IMSN. 
In the 9 patients with proven metastases to the IM lymph nodes without 
axillary lymph node metastases, it could be argued that there is an indication to 
perform an ALND, because their disease has shown that it is not just localised 
but has a metastatic potential. In our opinion there is no indication to perform 
axillary clearence in this subgroup of breast cancer patients. One of the reasons 
is that previous published studies concerning patients with breast cancer who 
all underwent a radical mastectomy, have shown that indeed there is a small 
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group of patients with IM metastases, without axillary metastases in the ALND 
specimen4. Based on the assumption that the SN accurately reflects the nodal 
status of the axillary basin, there is no need to perform an axillary lymph node 
dissection, in case of a negative axillary SN. Moreover, we did not encounter 
any axillary relapse in our own group of patients with negative axillary SN after 
a median follow-up of 42 months20. W e therefore feel that there is no indication 
to perform an ALND in this subgroup of breast cancer patients. 
Therapeutic consequences of IMSN biopsy 
It has been suggested that performing IMSN biopsy has little impact on adjuvant 
treatment. Indeed, only 3% of our entire study population proved to have IM 
metastases. However, when focusing on the group of breast cancer patients 
with proven IM lymph drainage as visualized on lymphoscintigraphy, the risk of 
IM metastases is substantial (22%). As for today, there is insufficient data to 
determine a positive effect of parasternal radiotherapy on survival in patients 
with proven IM metastases. However, axillary adjuvant radiotherapy in high-
risk subgroups, such as patients with more than 3 axillary metastases, is 
beneficial in terms of locoregional control21. As a consequence, parasternal 
radiotherapy was added to the treatment regime in our patients, in case of 
tumour-positive IMSNs. 
An ongoing randomized controlled trial of the European Organization for 
Research and Treatment of Cancer (EORTC 22922) is currently evaluating the 
impact of parasternal and medial supraclavicular irradiation on longterm 
disease-free and overall survival in breast cancer patients with centrally or 
medially located tumours. In contrast to studies which showed that the primary 
tumour site correlated with IM metastases, which was the rationale for the 
EORTC 22922 trial, our data show that the primary tumour site is not an 
accurate predictor for IM lymph drainage: lymphoscintigraphy showed IM 
hotspots originating from laterally located tumours in 37% of patients and 
internal mammary metastases were associated with lateral tumours in 42% of 
patients. In addition, IMSN biopsy in patients with medially or centrally located 
tumours showed no metastatic involvement in 80% (71/89) in our series. Thus, 
within the EORTC 22922 study, patients with lateral tumours and possible IM 
metastases are incorrectly deprived of additional parasternal radiotherapy, 
while patients with medial or central tumours receive parasternal radiotherapy 
without proof of internal mammary metastatic involvement. Since radiotherapy 
of the IM chain carries potential increased morbidity, the appropriate 
identification of patients who may benefit from adjuvant radiotherapy is 
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essential, and should be based on tumour-positive IMSN biopsy, rather than 
primary tumour site only. 
The impact of IMSN biopsy on altering adjuvant systemic therapy was 
relatively small in our series. It changed the adjuvant systemic treatment regime 
in 4 of the 31 IMSN positive patients. Micrometastases in axillary and internal 
mammary sentinel nodes is no indication for adjuvant chemotherapy according 
to Dutch National guidelines. Therefore, 3/31 patients with micrometastases in 
the IMSN did not receive adjuvant chemotherapy. Due to the presence of 
concommitant axillary metastases in 24 patients, 24/31 patients already would 
have received adjuvant chemotherapy. But considering the high incidence of 
breast cancer, this limited improvement in staging and treatment, may have an 
impact on many patients. 
Stage migration 
It might be argued that part of the effect of IM sentinel node staging does not 
really alter the prognosis, but merely results in stage migration. However, the 
effect of IMSN biopsy changes the AJCC stage distribution in only 9 Ax-/IMN+ 
patients, since they would have been classified stage I without the results of 
IMSN biopsy, but as stage 11A in 5 patients and as stage IIB in 4 patients as a 
result of IMSN biopsy22. Moreover, a large study, representing 8422 patients 
with a median follow up of 11 years, showed that medially located breast 
tumours are associated with worse prognosis. This suggests that it may be 
insufficient to rely on axillary staging alone to guide the selection of adjuvant 
treatment and that additional staging procedures, such as IMSN biopsy, offer 
the possibility of a more rational use of adjuvant systemic therapies23. 
CONCLUSION 
IMSN biopsy is feasible with little additional morbidity and improves nodal 
staging in breast cancer patients. In case of IM hotspots on lymphoscintigraphy, 
the risk of these nodes harbouring metastases is substantial (22%). With respect 
to the clinical relevance of IMSN biopsy, adjuvant treatment strategies were 
changed in all patients with IM metastases, by receiving adjuvant radiotherapy 
of the IM lymph node basin. Besides adjuvant radiotherapy, adjuvant 
chemotherapeutic regimes were changed in a small group of patients. 
Whether these treatment changes will show an improvement on prognosis 
in this high-risk subgroup of breast cancer patients remains to be awaited. 
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SUMMARY 
Although the internal mammary (IM) lymph node status is a major prognostic 
factor in breast cancer, IM nodal staging is not common practice. In order to 
improve nodal staging, we have routinely performed IM sentinel node (SN) 
biopsy and have adjusted adjuvant treatment accordingly. W e reviewed the 
outcome of these patients. Data from 764 patients were available for follow-up. 
A total of 406 patients had no lymph node metastases (group 1), 330 patients 
had axillary metastases (group 2), 7 patients had IM metastases only (group 3) 
and 21 patients had both axillary and IM metastases (group 4). Mean follow-up 
was 46 months. Prognosis did not appear to be worse for patients with IM 
metastases compared to those with axillary metastases only, which might 
indicate that they benefit from improved staging and tailored adjuvant 
treatment algorithms. However, long-term follow-up data, preferably in larger 
series, are needed to support our findings. 
86 
Outcome of patients with IMSN biopsy 
INTRODUCTION 
Axillary lymph node status is considered to be one of the most important 
prognostic factors in breast cancer. However, after long-term follow-up 15-30% 
of the patients classified as axillary node-negative will experience a treatment 
failure1. 
Since the introduction of the sentinel node (SN) concept for breast cancer in 
1993, this technique has evolved into the preferred method for staging the axilla 
in patients with breast cancer2,3. The SN technique also visualizes sentinel nodes 
(SNs) outside the axilla, mainly in the internal mammary (IM) basin. Metastatic 
involvement of the IM nodes (IMNs) has been demonstrated to be associated with 
a worse prognosis4,5,6. Thus, to obtain complete staging information, the SN 
technique should also be applied to the IMNs7. However, IMNs are not routinely 
harvested. Although several studies have shown that with IMSN biopsy it is 
possible to identify and selectively remove IMSNs with minimal morbidity7,8, 
controversy remains regarding its clinical relevance and the expected benefit in 
relation to potential morbidity. To date, no study has been conducted to 
determine the usefulness of IMSN biopsy in terms of survival benefit. 
We have routinely performed IMSN biopsy since the introduction of the 
SN technique, in order to improve staging by identifying higher-risk subgroups 
with internal mammary nodal metastases. Additional adjuvant chemotherapy as 
well as locoregional radiotherapy is being adjusted accordingly. The aim of this 
study is to evaluate treatment outcome of patients with IM lymph node 
metastases, who received tailored adjuvant treatment regimens. 
MATERIALS AND METHODS 
Patients 
From April 1997 to July 2004, after approval of the Local Ethical Committee, 
and after having obtained informed consent, 794 consecutive patients with 
clinically node-negative operable primary breast cancer were included in a 
prospective study on SN biopsy. No patients were excluded from SN biopsy, 
except for those who were pregnant or had a T4-tumor. For all patients, 
demographic data and data with respect to diagnostic procedures, treatment 
and follow up were gathered. Twenty-five patients with synchronous bilateral 
breast cancer or a diagnosis of invasive breast cancer before April 1997 and 5 
patients with incomplete follow-up were excluded from the current study, thus 
leaving 764 patients available for the analyses. 
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Our technique of sentinel node biopsy has been described in detail elsewhere9. 
The lymphatic mapping procedure consisted of a dual-tracer technique. During 
surgery in all patients attempts were made to harvest both axillary and non-
axillary SNs, as visualized by lymphoscintigraphy. A postoperative chest X-ray 
was made routinely following internal mammary node biopsy, to exclude 
accidental pneumothorax. 
Histopathologic examination of the sentinel nodes consisted of routine 
hematoxylin and eosin (H&E) staining, followed by serial sectioning and 
immunohistochemical staining whenever routine H&E staining did not reveal 
metastases. Patients with solitary tumour cells in the sentinel node (equal to or 
smaller than 0.2 mm) were considered to be node-negative. 
During the study period, patients received adjuvant systemic treatment 
according to the Dutch national guidelines. 
Patients with tumour-positive IMSN biopsy, for whom adjuvant systemic 
therapy was not already indicated as based on tumor size and/or axillary nodal 
status, received adjuvant chemotherapy and adjuvant hormonal therapy if ER-
positive. Additionally, all patients with 1MN metastases received adjuvant 
radiotherapy to the IM chain. Radiation therapy was administered to the IMNs 
in the three upper intercostal spaces. The intended dose was 50 Gy, given in 25 
fractions over 5 weeks. 
All patients were seen for follow-up every 3 months during the first year, 
every 6 months in the second year following surgery and once a year thereafter. 
Follow-up consisted of physical examination and a yearly bilateral or 
contralateral mammography. 
Statistical methods 
We studied the following end-points: breast cancer related death, for the 
analysis of breast cancer specific survival, and any relapse of breast cancer 
(locoregional recurrence, systemic recurrence) for the analysis of disease-free 
survival. Survival curves were estimated by the Kaplan-Meier method and 
compared by the logrank-test. A p-value < 0.05 was considered statistically 
significant. 
To be able to compare treatment outcome in the various subgroups, 
patients were divided into 8 subgroups as is illustrated in Figure 1. 
Breast cancer-specific survival and disease-free survival according to the 
nodal status was compared for 4 groups. Group 1 (subgroups ll+IV+VIII) 
consisted of patients, who proved to have no lymph node metastases at all (Ax-
IM-), group 2 (subgroups l+lll+VII) consisted of patients with axillary metastases 
only (Ax+IM-), group 3 (subgroup VI) consisted of patients with solitary IMN 
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Figure 1 Study population divided into 8 subgroups according to lymphoscintigraphy and SN 
biopsy. IMSN=internal Mammary Sentinel node; AxSN=Axillary Sentinel node 
metastases (Ax-IM+) and patients in group 4 (subgroup V) had both axillary and 
IM metastases (Ax+IM+). To adjust for potential differences in age, tumor size 
and tumor characteristics, we performed a multivariable analysis according to 
the Cox proportional hazards model. 
RESULTS 
Of the 764 included in this study, 408 (52%) had a T,-tumor, 333 (42%) aT2-
and 48 (6%) a T,-tumor. The preoperative diagnosis was made by fine-needle 
aspiration or core biopsy in 587 patients (77%) and by previous excisional 
biopsy in 177 patients (23%). 
Lymphoscintigraphy visualized axillary hot spots in 750 patients (98%). In 
166 patients (22%) additional hot spots were seen in the internal mammary 
chain, in 61% draining from medial or central tumors and in 39% from lateral 
tumors. Exclusive drainage to the IMNs was absent in our series. The axillary SN 
biopsy was successful in 98% (748/764). The axillary basin was tumor-positive 
in 46% (351/764) of the patients. Internal mammary sentinel node biopsy was 
successful in 69% (115/166) of patients showing parasternal hotspots on the 
scan and revealed metastatic involvement in 24% (28/115) (Figure 1). Of these, 
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6% (7/115) had a negative axillary SN biopsy (AX-/IMN+). In two patients, who 
were operated during the learning phase of the sentinel node procedure, a 
completion ALND confirmed this result. 
1MN metastases were associated with medial tumors in 14 patients, with 
lateral tumors in 11 patients and with subareolar tumors in 3 patients. 
IM-SN biopsy changed adjuvant systemic treatment in seven IM node-
positive patients (7/28=25%). Five of these were axillary node-negative. The 
remaining two patients were axillary node-positive and would initially have 
had only hormonal therapy, as based on their age over 60 years. Both were 
given additional chemotherapy, because of proven IM metastases. 
In 10 patients (10/166 =6%) IMSN biopsy resulted in a small pleural 
lesion. All cases were noted intraoperatively. Initially, this was treated with 
simple vacuum drainage in 4 patients. The remaining patients received no 
specific treatment and all patients recovered uneventfully, as was confirmed by 
chest X-rays. 
Median follow-up was 43 months (mean 46 months, range 14-102). For 
the survival analysis, the total group of 764 patients was divided into four 
groups, according to the lymph node status. Group 1 consisted of 406 patients, 
who proved to have no lymph node metastases (Ax-IM-), group 2 consisted of 
330 patients with axillary metastases (Ax+IM-), group 3 consisted 7 patients 
with solitary IM metastases (AX-IM+) and patients in group 4, a total number of 
21 patients, had both axillary and IM metastases (Ax+IM+). The breast cancer-
specific survival and disease-free survival rates between group 1 (Ax-IM-) and 
group 2 (Ax+IM-) differed significantly (p<0.0001), favoring group 1 as can be 
expected (Table 1 and Figure 2). 
Table 1 Five-year breast cancer specific survival (BCSS) and S-year disease-free survival (DFS), 
according to nodal status 
n BCSS (%) (95% CI) 
(%) 
DFS 
(%) 
(95% CI) 
AX-/IM-(group 1) 406 95 (92-98) 
Ax+/IM-(group 2) 330 84 (79-89) 
Ax-/IM+(group 3) 7 82 (50-100) 
Ax+/IM+(group 4) 21 89 (75-100) 90 
86 
81 
92 
(77-100) 
(60-100) 
(76-86) 
(89-95) 
SE: standard error; 95% CI: 95% confidence interval 
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N o s i g n i f i c a n t d i f f e r e n c e s w e r e o b s e r v e d in breast cance r - spec i f i c a n d disease-
f ree su rv i va l b e t w e e n pa t i en ts w i t h i n t e rna l m a m m a r y metastases (g roup 3 a n d 
4) a n d pa t i en ts w i t h o u t l M - l y m p h n o d e metastases ( g r o u p 2) (Table 1 a n d Figure 
2 ) . T h e p r o g n o s t i c e f f e c t o f l y m p h n o d e s ta tus w a s c o n f i r m e d by t h e 
m u l t i v a r i a b l e ana l ys i s (Tab le 2). O t h e r s i g n i f i c a n t p r o g n o s t i c fac tors , bes ides 
n o d a l status, w e r e t u m o r s ize, h i s t o l o g i c g rade a n d es t rogen recep to r status. 
Table 2 Results of multivariable analysis, according to the Cox proportional hazards model, for 
disease-free survival (n=693) 
Characteristic _ _ HR J 9 5 ° A ü > p"v.?llJe 
Age at diagnosis (years) 
<=50 1 (Ref) 
51-70 0.85 (0.52-1.39) 0.522 
>70_ 0.78 (0.42-1.45) 0427 _ 
Nodal status 
AX+/IM- 1 (Ref) 
AX-/IM- 0.55 (0.34-0.90) 0.017 
AX+/IM+ 0.61 (0.19-1.98) ' 0,408 
AX-/IM+ 1.35 JO. 18-9.97) 0.771 
Pathological tumor size (mm) 
£20 1 (Ref) 
>20 _ 3.40 _ (1.92-6.00)_ _ _ <0.00[ 
Estrogen receptor status 
Positive 1 (Ref) 
Negative _ _ _ 1.67 _ ( l i 0 5 : 2 M _ _ . 0 : ° i L 
Progesterone receptor status 
Positive 1 (Ref) 
Negative 131 ______ _____ (0.75-2.29) 0.348 
Tumor grade 
Low 1 (Ref) 
Intermediate 3.94 (1.19-13.04) 0.025 
High 6.50 (2-00;21J6) _ _ J'0??.. 
HR: hazard ratio; 95% CI: 95% confidence interval; Ax= axillary lymph nodes, IM= internal mammary lymph nodes, 
(+)= positive for metastases, (-)=negatlve for metastases 
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Figure 2 Disease-free survival, according to axillary and internal mammary nodal status. 
Ax= axillary lymph nodes, IM= internal mammary lymph nodes, (+)= positive for metastases, 
(-)=negative for metastases 
D I S C U S S I O N 
The importance of the IMNs as a lymphatic drainage pathway from the breast 
has been confirmed in numerous studies10,11'12,13. As a consequence, radical 
dissection of the internal mammary chain became part of the standard surgical 
treatment for breast cancer in the 1950s and 1960s. Various studies from that 
time, concerning this radical surgical treatment, are still the main source of 
information on the extent of nodal involvement in the internal mammary 
basin4,6,14,15,16,17. The overall prevalence of IMN metastases in these studies 
varies from 18 to 33%, mostly concomitant with axillary metastases. During the 
1970s internal mammary lymph node dissection was abandoned, based on 
patient outcome studies, which showed that the procedure did not improve 
patients' prognosis5,6,15,16,17. However, these studies clearly demonstrate that 
the presence of metastases in the IM chain is associated with a poor prognosis 
(Table 3). 
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Table 3 Overall survival (OS) rates in relation to lymph node status in breast cancer patients. 
n= number of patients, Ax= axillary lymph nodes, IM= internal mammary lymph nodes, (+)= positive for metastases, (-)=negative for metastases 
Study Follow-up n Ax-/IM- vs.Ax-/IM+ Ax+/IM- vs. Ax+/ IM+ 
Ax-/IM- AX-/IM+ Ax-h/ll VI- Ax+/ IM+ 
n OS n OS n OS n OS 
Caceres, 196754 5 year 425 175 84.6% 9 55.5% 170 51.7% 71 23.9% 
Urban, 197158 5 year 500 228 87% 36 64% 124 68% 112 54% 
10 year 315 144 75% 23 52% 73 53% 75 21% 
Donegan, 19775 5 year 105 45 67% 2 0% 40 35% 18 28% 
10 year 101 43 40% 2 0 % 38 21% 18 6% 
Veronesi, 19834 10 year 995 467 82.1% 44 62.4% 346 59.6% 138 37.3% 
Cody, 19956 5 year 195 98 88.8% 22 70.2% 48 86.1% 27 61.1% 
10 year 195 98 81.3% 22 58.5% 48 73.4% 27 53.0% 
Horino, 199119 10 year 289 139 92% 14 67% 91 67% 45 40% 
Sugg, 200020 20 year 286 130 16%* 7 28%* 84 46%* 65 23%* 
* Disease-free survival; Ax= axillary lymph nodes, IM= internal mammary lymph nodes, (+)= positive for metastases, (-)=negative for metastases 
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The wide range of reported survival rates may be attributed to the small sample 
sizes of some studies and the use of different adjuvant treatment protocols. 
Survival for patients with metastases exclusive to the IM nodes was in most 
studies comparable to the outcome of patients with solitary axillary metastases, 
ranging from 50% to 70% for Ax-IM+, compared to 51 % to 86% for Ax+IM-. In 
most studies, the number of patients with both axillary and IM metastases was 
too small to make comparisons. However, in the largest study, by Veronesi et 
al., this group has a significantly worse prognosis than the other groups. 
In contrast to the studies presented in Table 3, no statistically significant 
differences in overall survival and disease-free survival were observed in our 
study between IM node-negative and IM node-positive patients. Although we 
are aware that the subgroup of patients with positive IMN's is small and follow-
up still relatively short, this seems to suggest that the tailored adjuvant systemic 
therapy and additional parasternal radiotherapy has had a beneficial effect on 
the prognosis of these patients. 
The optimal treatment of IM metastases remains controversial. 
Randomized controlled trials have shown a survival benefit in patients 
undergoing radiotherapy to the chest wall and locoregional lymph nodes 
(including the IM chain) after mastectomy21,22. These studies indicate that 
elimination of locoregional cancer cells by radiotherapy, added to adjuvant 
chemotherapy, may reduce mortality in selected patients with breast cancer. 
An ongoing European Randomized controlled trail (EORTC 22922) is 
currently evaluating the impact of IMN and medial supraclavicular irradiation 
on longterm disease-free and overall survival in selected breast cancer patients 
with centrally or medially located tumours. 
Although it is true that the primary tumor site correlated with IM 
metastases, which was the rationale for the EORTC 22922 trial, our data show 
that tumor site is not a very accurate predictor for IM lymph drainage. In our 
study lymphoscintigraphy showed IM hotspots originating from laterally located 
tumours in 44% of patients with IM hotspots. These patients may, incorrectly, be 
deprived of adjuvant radiotherapy. In addition, IMSN biopsy in patients with 
medially or centrally located tumours showed no metastatic involvement in 
76% (51/67) in our series. These specific features of IM lymph drainage, may 
lower the power of the EORTC trial 22922 to reveal the benefits of IM node 
irradiation. Since radiotherapy of the IM chain is not without risks, the 
appropriate identification of patients who may benefit from adjuvant 
parasternal radiotherapy is essential and should, in our opinion, be based on 
histological confirmation of nodal involvement, as obtained by IMSN biopsy, 
and not merely on tumor location or confirmed IM tumour lymph drainage. 
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Metastatic involvement of the IM chain is also an indication for adjuvant 
systemic therapy. However, patients with IM node-positive disease generally 
already receive adjuvant systemic therapy, based on the concomitant axillary 
metastases. Therefore alteration in treatment is confined to patients with 
metastases solely in the IM chain. 
Our overall data showed that IM node status resulted in a change of the 
adjuvant treatment plans in only 3.4% (27/789) of the patients. One may argue 
that this proportion is too small to justify the use of IMSN biopsy. However, 
since we found IM-metastases in 16% (27/169) of patients with visualized 
lymph drainage to the IM nodes and in 23% (27/116) of all successful IM-SN 
biopsies, it can be concluded that the presence of IM drainage patterns on 
lymphoscintigraphy is associated with a substantial risk of IM-metastases, 
encouraging removal of these IM sentinel nodes. Thus, optimal nodal staging 
can be achieved, allowing for tailored treatment strategies, based on individual 
risk profiles. 
CONCLUS ION 
Although the presence of IMN metastases indicates advanced locoregional 
disease, with decreased survival rates, the status of the IM nodes remains 
unknown in most patients with breast cancer today. IMSN biopsy in breast 
cancer is technically feasible and improves nodal staging. This technique helps 
to identify a higher-risk subgroup with IM metastases. Considering the high 
incidence of breast cancer, by which an improvement in the outcome of 
treatment, even in limited subgroups, may result in a substantial contribution to 
breast cancer therapy, we believe that evaluation of the sentinel nodes in the IM 
chain should be performed routinely, and proven IM metastases should be 
treated accordingly. Our results indicate that such a strategy could improve the 
prognosis of patients with IM metastases. However, long-term follow-up data, 
preferably in larger series, are needed to support our findings. 
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ABSTRACT 
Objective 
Metastases in the internal mammary (IM) lymph nodes have an important 
prognostic value in breast cancer. Lymphatic mapping and sentinel node (SN) 
biopsy of IM nodes improves staging and permits specific therapeutic strategies, 
thereby possibly improving final outcome. Therefore, optimal lymphoscintigraphic 
results are needed. Visualization of IM lymph drainage however is influenced by 
several factors. We evaluated the effect of different time intervals between 
radioactive tracer injection and lymphoscintigraphy on visualization of internal 
mammary sentinel lymph nodes. 
Methods 
From February 1997 to August 2001 a total of 682 eligible breast cancer 
patients underwent sentinel lymph node mapping. The technique involved the 
injection of 10 mCi {370 MBq) "mTc-nanocolloid peritumorally. In 470 patients 
(group A) the time interval between injection of the radiocolloid and 
lymphoscintigraphy was 16 hours, compared to 2.5 hours in 212 patients 
(group B). 
Results 
Patient characteristics showed no statistically significant difference between 
both groups for age and location of the tumour. Axillary hotspots were 
visualized in 97% in group A and 96% in group B. Lymphoscintigraphy showed 
internal mammary hotspots in 21% in group A, compared to 27% in group B. 
The mean number of IM hotspots per patient was 1.9 in group A and 1.8 in 
group B. 
Conclusions 
W e found no significant differences between early and delayed lympho-
scintigraphic imaging in visualizing internal mammary sentinel lymph nodes. 
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INTRODUCTION 
Since the introduction in 1993 of the SN concept , it quickly evolved into a 
generally accepted and world-wide applied method for staging in breast 
cancer1. Many validation studies confirmed the accuracy of the SN biopsy in 
predicting the status of the axillary lymph nodes2"6. Axillary lymph node 
dissection is nowadays abandoned in case of negative pathological findings in 
the axillary SN. 
The technique of lymphatic mapping inevitably confronts us with the 
visualization of non-axillary lymphatic draining patterns, and the question of 
their clinical relevance. Previous studies showed that the tumour-status of the 
internal mammary SNs represents a major independent prognostic factor in 
breast cancer7. Although axillary sentinel nodes are routinely evaluated, IM 
lymph nodes are not routinely biopsied or included in staging. As for axillary 
SN biopsy, harvesting of the internal mammary nodes, based on lympho-
scintigraphy, will have implications for staging and treatment8. 
The results of preoperative lymphoscintigraphy therefore should be 
optimal. 
However, the visualization rate of internal mammary nodes on lympho-
scintigraphy is influenced by several different factors. In order to establish an 
optimal IM-imaging protocol within the complex logistics of planning 
preoperative lymphoscintigraphy and SN surgery, we conducted a study to 
determine whether different time intervals between injections of a radioactive 
tracer and performing lymphoscintigraphy affect the visualization rate of 
internal mammary hotspots. 
METHODS 
Based on a prospective database, following approval of the local ethics 
committee and after obtaining informed consent, a cohort study was performed 
in 682 clinically node-negative T 1-3 breast cancer patients. Ail patients 
underwent preoperative lymphatic mapping for SN biopsy from February 1997 
to August 2001. Data for group A, consisting of 470 consecutive patients, were 
collected from a single institution. Group B consisted of 223 patients from two 
other hospitals in the same region. In the latter, insufficient data for analysis 
were available in 11 patients, resulting in 212 eligible patients in group B. 
A two day protocol for SN biopsy was administered for both groups. 
Lymphatic mapping was performed by the same nuclear medicine physicians 
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for both groups, preventing bias in individual technical performance. Our 
technique of SN biopsy has been described in detail elsewhere2. The day before 
surgery in both groups 10 mCi (370 MBq) "mTc-nanocolloid in 4 ml saline was 
injected peritumorally in 3-4 depots around the tumour or in the breast 
parenchyma surrounding the cavity of a previous excisional biopsy. For group A 
delayed lymphoscintigraphy was performed on the next day, after a mean 
period of 16 hours (range 16-18 hours ) following radiotracer injection, and 
shortly before surgery. For group B early lymphoscintigraphic images were 
obtained the same day after a mean period of 2,5 hours (range 2-4 hours) after 
the injection of the radiocolloid tracer and surgery was performed the next day. 
Scintigraphic images in all patients were obtained in three positions: 
anterior, anterior-oblique and lateral in order to visualize the number of SNs 
and their axillary and non-axillary position. 
Statistical analysis was performed using student t Test for continuous 
variables and for discrete variables Chi-square analysis was used. P value < 
0.05 was considered statistically significant. 
RESULTS 
Lymphatic mapping and SN biopsy was performed in 470 patients in group A 
and in 212 patients in group B. Patient characteristics are listed in Table 1. 
Comparing the two groups, no statistical significance was reached for age and 
location of the tumour. Tumour diameter was also similar, but histology showed 
more lobular tumours in group A and more ductal carcinomas in group B. 
The results of preoperative lymphoscintigraphy with visualization of 
axillary and internal mammary hotspots in both groups are listed in Table 2. 
Detection of axillary hotspots on lymphoscintigraphy was almost equal in both 
groups (97% in group A and 96% in group B). The lymphoscintigraphic 
detection of lM hotspots was 21%(99/470) after delayed imaging (group A) and 
27%(58/212) after early imaging (group B). Drainage to the IM lymph nodes 
originated from laterally located tumours in 41% (41/99) and in 59% (58/99) for 
central or medially located tumours in group A. For group B, IM drainage 
originated from laterally located tumours in 28/58 (48%) patients and from 
central or medially located tumours in 30/58 (52%). 
The mean number of IM hotspots per patient was 1.9 in group A and 1.8 
in group B. 
The differences in the rate of internal mammary visualization did not 
reach statistical significance (P value> 0.05). 
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The mean age of patients showing I M drainage was 54 years in group A and 56 
years in group B. 
The detection of internal mammary hotspots was influenced by age, as is 
shown in Table 3. The proportion of patients with internal mammary hotspots 
decreases wi th age. This effect was seen in both groups. 
Table 1 Patient characteristics of group A and B 
Delayed imaging Early imaging 
Group A Group B 
(N—470) ___ _ _ (N=212) ___ 
Mean age (years) 59 (range 28-96) 58 (range 30-87) 
SD 12.0 SD 12.9 
Tumour characteristics _ 
Diameter 
<20 mm 221 (47%) 115(54%) 
20-49 mm 214(46%) 90(42%) 
_>49mm 35(7%)_ __ _ 7(3%) 
Ductal cardnorria ' ~ 324(69%) I J I J M W ' ' . 
Lobular"carcinoma __ " " 1 1 1 2 W W ~ ~ T I I 
Other J 34(7%) ~ " ' 1 ( 4 % ) ^ 
Left " 262 (56%) 106 (50%) " 
Right 208(44%) 106 (5C%) 
Breast quadrant 
Upper-outer 216(46%) 99(47%) 
Upper-inner 102(22%) 41(19%) 
Lower-outer 58(12%) 29(14%) 
Lower-inner 55(12%) 17(8%) 
Central 36(7%) 22(10%) 
Unknown 3(1%) 4(2%) 
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Table 2 Lymphoscint igraphic v isua l izat ion o f hotspots in g roup A and B 
Delayed imaging Early imaging P value 
Group A Group B 
(N=470) (N=212) 
Patients with axillary hotspots 454 (97%) 203 (96%) 0.75 
Total axillary hotspots 629 369 
Mean axillary hotspots (range) 1.4(1-7) 1.7(1-5) 
SD 1.0 SD 1.0 
Patients with additional IM hotspots 99 (21%) 58(27%) 0.09 
Total IM hotspots 191 107 
Mean IM hotspots (range) 1.9 (1-6) 1.8(1-5) 
SD 1.0 SD 0.9 
Only IM hotspots 0 0 
Table 3 The cor re la t ion between age and internal m a m m a r y hotspots on lymphosc in t ig raphy in 
group A and B 
Delayed imaging Early imaging 
Group A Group B 
(N=470) (N=212) 
Age (years) N I M hotspots N I M hotspots 
<40 32 12(38%) 11 4(36%) 
41-50 114 40 (35%) 47 19(40%) 
51-60 126 19(15%) 64 18(28%) 
61-70 95 15(16%) 50 8(16%) 
>70 103 13(13%) 40 9 (23%) 
DISCUSSION 
The lymphatic drainage of the breast has been studied intensively. Halsted 
identified the internal mammary chain as a route of metastases in breast cancer 
in 1907. Many subsequent studies have conf irmed the importance of the 
internal mammary basin as a second draining route in breast cancer9,10. 
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As a consequence, internal mammary lymph node dissection was part of the 
standard surgical treatment in the 1950s and 1960s. Studies concerning this 
radical surgical treatment are the main source of information on the extent of 
nodal involvement in the internal mammary basin. Survival rates proved to be 
worse in case of internal mammary metastases7,11. 
During the 1970s internal mammary dissection was abandoned, based on 
patient outcome studies, which showed unfavourable survival rates, but no 
improvement on prognosis after radical dissection of the internal mammary 
chain. 
Following the introduction of the SN technique, however, the internal 
mammary basin has regained interest. In patients with documented internal 
mammary lymphatic drainage, IM SN biopsy adds to adequate staging by 
identifying IM node-tumour positive patients. The less favourable prognosis in 
these patients thus can be influenced by tailoring their individual adjuvant 
treatment programs8, in order to benefit final outcome. 
Optimal visualization of both axillary and non-axillary lymph drainage 
patterns is mandatory to reach accurate lymphatic mapping and staging. 
Whether a one clay protocol or a two day protocol is used often is a matter 
of logistic preference, but neither should have a negative effect on the 
lymphoscintigraphic results. 
In a one day protocol, tracer injection, lymphoscintigraphy and SN biopsy 
are performed on the same day, thereby avoiding the patient's need for an extra 
hospital visit. 
In a two day protocol, tracer injection can be followed by lympho-
scintigraphy on the same day or the next clay, i.e. the clay of surgery. A two clay 
protocol has advantages both in scheduling multiple patients for lympho-
scintigraphic imaging as well as in planning the operating room (OR) schedule, 
facilitating the planning of multiple SN procedures at the same day. Moreover, 
a two clay protocol has radiation safety advantages, showing a significantly 
decreased dosage of radioactivity in the resected specimen12 and a smaller 
absorbed radiation dose to the hands of the medical staff due to radioactive 
decay13,14. 
Late lymphoscintigraphic imaging on the day of surgery has the advantage 
of visualizing the SN without the risk of registering confusing temporary 
radiocolloid accumulations in lymphatic tracts. 
It has been suggested that a longer interval between radioisotope injection 
and scanning results in a greater number of IM SNs on the lympho-
scintigraphy15,16. While using a two clay protocol in both group A and group B, 
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we analysed the effect of early lymphoscintigraphic imaging (group B) as 
compared to delayed imaging (group A) in visualizing internal mammary SNs. 
In this study, we found no statistical significant differences between IM SN 
visualization in group A (21%) and group B (27%) 
Hence, we could not demonstrate a correlation between timing of the 
radiotracer injection and the lymphoscintigraphic detection of IM SNs, 
However, there is a wide range of reported visualization of internal 
mammary hotspots in lymphatic mapping for SN biopsy. Published results differ 
mainly, because the detection rate is influenced by other several technical, 
anatomical and biological factors. 
The most important factor is the site of tracer injection. While aiming for 
improved accuracy, various injection sites for the radiocolloid are used, such as 
intracutaneous, subareolar, peritumoral, intratumoral, subtumoral and 
periareolar injections. Although axillary lymph drainage patterns are 
independent of the site of tracer injection5,17, internal mammary lymph 
drainage is not. Visualization of the internal mammary nodes is rarely seen 
following intra- or subcutaneous, subareolar or periareolar tracer injections, as 
compared to peritumoral, intratumoral or subtumoral tracer injections. This 
suggests that the breast parenchyma drains to both the axilla and the internal 
mammary chain, but the skin overlying the breast only has a lymphatic 
drainage to the axilla. 
Shimazu and Paganelli compared superficial and deep parenchymatous 
injection of a tracer18,19. Internal mammary hotspots were more frequently seen 
after deep tracer injections. This was associated with more internal mammary 
metastases found for deep located tumours, compared to superficially located 
tumours. 
A second factor that influences the visualization of IM lymphatic drainage 
is the localisation of the tumour. Anatomical considerations suggest that 
medially located intraparenchymatous injections will result in an increased rate 
of internal mammary hotspots. However, the results in the literature are 
inconsistent. Early anatomic studies by Hultborn (1955) and Turner-Warwick 
(1959) conclude that both the medial and lateral halves of the breast show 
similar drainage rates to the internal mammary chain9,10. Our own, previously 
published, results showed internal mammary drainage in 65 (25.3%) of 256 
patients, in 63% draining medial or central tumours, and in 37% draining lateral 
tumours8. These results are in accordance with other studies19,20, which confirm 
that tracer administration in the medial or central quadrants of the breast 
parenchyma is associated with increased rates of internal mammary hotspots. 
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However it is possible that these findings have no relationship with tumour 
location itself, but can be explained by what Krynyckyi21 called a proximity-
effect. He noted that in small breasts the chances of detecting IM-SNs were 
much higher, since the lesion and therefore the tracer injection would be much 
closer to the chest wall and the deeper lymphatic channels that course to the 
parasternal IM-SNs. This hypothesis is concordant with the effects of deep 
subtumorai tracer injection as mentioned by Shimazu18. 
A third factor influencing parasternal hotspot visualization is the particle 
size of the different tracers. After injection, a colloid tracer is absorbed into the 
lymphatics and transported through the lymph channels. Smaller particles flow 
more easily through the lymphatics and are retained in the macrophages of the 
lymph node for a relative short period, as compared to larger colloids18,22. 
While using radioactive gold (198Au), which has a small particle size, Hultborn 
described parasternal radioactive uptake in all patients9. Using "mTc-antimony 
sulphide, Uren reported parasternal drainage in 35% of his patients21. In 
Europe "mTc- nanocolloid is used with a particle size larger than radioactive 
gold and "mTc-antimony sulphide colloid. The "mTc-sulfur colloid, 
commonly used in the United States, has the largest particle size of the 
radiocolloid tracers mentioned. Consequently, these differences in particle size 
contribute in the varying reports regarding lymphoscintigraphy visualization of 
IM hotspots. 
Yet another factor that influences the pattern and speed of lymph drainage 
is increasing age2'1,2&. It appears that patient age is inversely correlated with the 
ability to identify axillary SNs. This is related to the induction of fatty 
degeneration of breast parenchyma in postmenopausal women. The lymphatic 
capillaries of the breast are confined to the ducto-lobular complexes, in 
contrast to fatty tissue which contains scarcely any lymphatics. 
We evaluated the effect of age on the visualization of internal mammary 
hotspots. Our results confirmed that, like axillary drainage, internal mammary 
drainage is affected by increasing age (Table 3). 
Besides all the above-mentioned issues that influence visualization of 
parasternal hotspots, it is suggested that the ability to retain radioactivity is 
different for axillary lymph nodes, as compared to parasternal lymph nodes1". 
Radiocolloid is said to be retained for a shorter time in the internal mammary 
SN than in the axillary SN. If so, this would suggest that less internal mammary 
nodes would be seen in group A patients, based on the longer time interval 
between radioactive tracer injection and lymphoscintigraphy. Indeed, we found 
less IM hotspots in group A (21%) as compared to group B (27%), but the 
difference between both groups was not statistically significant. 
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Another variable which could affect IMN visualization is the amount of 
radioactivity used. However, our results can not distinguish whether increased 
tracer activity is associated with IMN visualization, since all patients received 
the same dose of 10 mCi (370 MBq) q9mTc-nanocolloid. Published data of 
Estourgie et al, using intratumoral injection of 3 mCi 99mTc-nanocolloid 
showed IM hotspots in 22% (150/691), which is comparable to our results27. 
CONCLUSION 
Internal mammary metastases are increasingly being recognized as having 
important prognostic significance in breast cancer. Since internal mammary SN 
biopsy is feasible, and capable of identifying these high-risk IM node-positive 
patients, factors influencing parasternal hotspot visualization have regained 
interest. 
In search of the optimal logistical and technical protocol for internal 
mammary lymphatic mapping, we evaluated the effect of different time interval 
between radioactive tracer injection and lymphoscintigraphy on visualization 
of internal mammary SNs. We found no statistically significant differences 
between early and delayed lymphoscintigraphic imaging protocols in this study. 
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ABSTRACT 
Introduction 
Precise localisation of sentinel nodes (SNs) outside the axilla is a major concern 
when interpreting lymphoscintigraphy. SPECT/CT is a recent non-invasive 
technique, providing spatial anatomical information. The purpose of this study 
was to investigate whether SPECT/CT is beneficial in lymphatic mapping 
compared to lymphoscintigraphy alone, in patients with internal mammary (IM) 
hotspots. 
Material and methods 
All consecutive patients from 2006 up to 2008 with a cT1-3N0 breast 
carcinoma with IM hotspots on lymphoscintigraphy were prospectively 
included. Lymphoscintigraphy was followed by SPECT/CT in all patients with 
IM hotspots. Differences between the lymphoscintigraphy and the SPECT/CT 
with respect to the number and location of hotspots as well as the surgical and 
pathological results were analysed. 
Results 
Forty-two consecutive patients were included. In 16 patients (38%), the 
SPECT/CT provided no additional information compared to lymphoscintigraphy 
alone. In 5 patients (12%) SPECT/CT provided additional information, but 
without surgical consequences. 
In the remaining 21 patients (50%) the SPECT/CT results had a substantial 
impact on the surgical procedure. In 2 patients (4.8%), the SPECT/CT showed 
additional SNs. In 20 patients (47.6%) the SPECT/CT results gave substantial 
reason not to explore the SN as visualised on the lymphoscintigraphy. 
Conclusions 
SPECT/CT has a major impact on surgical decision making compared to 
lymphoscintigraphy alone in patients with IM hotspots on lymphoscintigraphy. 
It improves the localisation and increases the number of visualized SNs and, 
more importantly, it reduces the number of non beneficial explorations. 
Keywords 
Breast cancer, internal mammary sentinel node biopsy, SPECT/CT, lympho-
scintigraphy. 
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INTRODUCTION 
Lymphatic mapping and sentinel node (SN) biopsy has become the standard of 
care for determining disease stage, appropriate therapy, and prognosis in 
clinically lymph node negative patients with breast cancer1. The SN is usually 
identified using a double tracer technique, combined with preoperative 
lymphoscintigraphy and a hand-held gamma probe. 
The axillary lymph node status is considered the most important 
prognostic factor in breast cancer. However, in patients classified as axillary 
node-negative, long-term follow-up shows treatment-failure in 15-30% of 
patients.2 Previous research has shown that not only the axillary lymph node 
status but also metastatic involvement of the internal mammary (IM) lymph 
nodes is an important independent prognostic factor in breast cancer3. 
Lymphatic mapping visualizes SNs both in and outside the axilla. As for 
axillary SN biopsy, harvesting of the IM nodes, based on lymphoscintigraphy, 
will have implications for staging and treatment4"'1.This procedure is not 
routinely performed in contemporary surgery, but the prognostic implications of 
metastatic involvement outside the axilla has led to the conclusion that IM SN 
biopsy needs to be considered to improve staging. Currently, IM SN biopsy is 
routinely performed in several institutions. 
Precise localisation of hotspots is a major concern when interpreting 
lymphoscintigraphy. Intra-operative identification of axillary SNs can be 
achieved in the vast majority of cases. However, with respect to the 
identification of SNs outside the axilla, the lack of spatial resolution and 
anatomical detail are a major difficulty. The use of SPECT/CT (Single-Photon 
Emission Computed Tomography/Computed Tomography) is a recent non-
invasive technique that combines the functional information of SPECT with the 
anatomical information provided by CT and has successfully been used in recent 
studies. These studies show a higher accuracy of the SPECT/CT in the detection 
and localization of SNs as compared to conventional lymphoscintigraphy7"". 
The purpose of this study was to investigate whether SPECT/CT has a significant 
influence on the surgical decision making, as compared to conventional 
lymphoscintigraphy alone, in patients with breast cancer with IM hotspots on 
lymphoscintigraphy. 
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MATERIAL AND METHODS 
Patient population 
From January 2006 till January 2008 all consecutive patients with a cT1-3N0 
breast carcinoma with IM hotspots were prospectively included in a database. 
Patients with a clinically positive axilla and patients who had received 
neoadjuvant therapy were excluded. 
Imaging and surgical protocol 
Lymphatic mapping and SN biopsy were performed, using a 2-day protocol 
which has been described previously4. 
Lymphoscintigraphy was performed 1 6 to 18 hours (average 16.5 hours) 
after peritumoral injection of 370 MBq (10 mCi) Tc-99m nanocolloid 
(Nanocoll, Gipharma Sri, Saluggia, Italy) in 4 ml saline (0.9% NaCI). Lympho-
scintigraphic images were obtained in three standard positions: anterior, 
oblique and lateral. Acquisition time was five minutes per view or a minimum 
of 800 kcounts per image. In case no axilarry hot spot was visualised, an 
additional tracer injection of 37MBq (1 mCi) Tc-99m nanocolloid was 
administered intradermally above the tumour. The location of axillary and non-
axillary SNs was marked on the skin. In all patients with hot spots outside the 
axilla, lymphoscintigraphy was followed by SPECT/CT. SPECT/CT was 
performed in a supine position with both arms above the head. A non-contrast-
enhanced low-dose CT of the field of view of the SPECT covering the chest and 
neck was performed with a slice thickness of 2.5 millimetres. The consecutive 
SPECT was performed over one field of view (128 x 128 matrix, axial length: 
512 millimetres) including the chest and neck. The images were obtained in 32 
steps /180° per head, with an acquisition time of 45 seconds per step and 
reconstructed with filter backprojection Butterworth order 0.35 offset 5. The CT 
data were used for attenuation correction and image fusion. The resulting total 
acquisition time of the SPECT/CT was about 27 minutes. Image analysis of the 
lymphoscintigraphy and SPECT/CT was performed by two experienced nuclear 
medicine physicians and five radiologists. 
All SN procedures were performed by three experienced surgeons or 
under their supervision by a senior resident. Shortly before incision, 0.5-0.8 ml 
Patent Blue V (Laboratoire Guerbet, Villepinte, France) was injected 
intradermally above the tumour. Intraoperative identification of the SNs was 
based on both blue dye mapping and gamma probe detection (EuroProbe, 
EuroMedical Instruments, Strasbourg, France). According to local consensus, 
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the intended goal was to harvest both axillary and non-axillary SNs, as 
visualized on lymphoscintigraphy and SPECT/CT. If necessary, additional small 
incisions were used to harvest non-axillary SNs. If the SN was in an 
inaccessible position behind the rib, partial ribsesection was not performed, 
and the SN was left in situ. A postoperative chest X-ray was made routinely 
following IM node biopsy, to exclude pneumothorax, resulting from accidental 
pleural lesion. In case no axillary hotspot was visualized on the 
lymphoscintigraphy, the axilla was explored using the blue dye technique. 
Analysis 
Patient characteristics and the differences between the lymphoscintigraphy, and 
the SPECT/CT with respect to the number, and location of the hotspots together 
with the surgical, and histopathological/immunohistochemical results were 
recorded prospectively in the database. The concerning specialists were not 
aware of the current analysis. Data were analysed using descriptive statistics. 
RESULTS 
Patient population 
From January 2006 to January 2008, a total of 42 consecutive patients with a 
cT1-3N0 breast carcinoma with IM hot spots on the lymphoscintigraphy 
received a SPECT/CT and were prospectively included in the database. The 
average age was 54.8 years (SD: 10.9; range: 30-78). 
Imaging and surgical results 
In 13 out of the 42 patients (30.9%), the SPECT/CT provided no additional 
information compared to lymphoscintigraphy alone (Figures 1 and 2). 
In 5 patients (11.9%) the SPECT/CT provided a closer determination of the 
w 
r fc , . 
Figure 1 A: anterior-posterior lymphoscintigraphy showing 1 axillary and 2 internal mammary 
(IM) hotspots. The lateral view (B) and the oblique view (C). The location of the most caudal 
located (IM) hotspot is depicted in figure 2. 
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IHl 
anatomical location of the hotspot, but this had no consequences for the 
surgical procedure. In a further 2 patients (4.8%) the lymphoscintigraphy turned 
out to be more accurate than the SPECT/CT. In both cases, the lympho-
scintigraphy showed two parasternal hotspots, which on the SPECT/CT 
appeared to be retrosternal, but revealed to be parasternal nevertheless during 
surgery. The SN retrieval in one of the two patients was complicated by a 
pneumothorax, an indication that a borderline position between retro- and 
parasternal was probably the case. In 1 patient (2.4%) both lymphoscintigraphy 
and SPECT/CT located the SN retrosternal, but it appeared to be parasternal 
during surgery. 
In the remaining 21 patients (50%) the 
SPECT/CT results had a major impact 
on the surgical procedure. 
In 2 patients (4.8%), the SPECT/ 
CT showed additional hot spots. One 
patient proved to have an additional 
supraclavicular SN and one patient had 
an additional axillary hotspot, which 
was not visualised on the lympho-
scintigraphy. Both SNs could be 
removed during surgery. Histopatho-
logical examination showed no signs of 
metastasis. Besides the additional 
hotspots, one of these patients had an 
IM hotspot on the conventional 
lymphoscintigraphy, which appeared to 
be inaccessible on SPECT/CT. 
In 20 patients (47.6%) the SPECT/ 
CT results gave substantial reason not 
to explore the hotspot as visualised on 
the lymphoscintigraphy. In 13 patients, 
with a total of 14 IM hotspots on the 
planar images, due to the finding that 
one or more IM hotspots on the 
lymphoscintigraphy could be associa-
ted with an intrathoracic (in 9 
Figure 2 Transaxial SPECT/CT images hotspots), retrosternal (in 2 hotspots), or 
confirm parasternal location of the internal retrocostal (in 3 hotspots) posit ion, a l l 
mammary hotspot. with an anatomic substrate on the 
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Figure 3 A: anterior-posterior lymphoscintigraphy showing I axillary hotspot and 3 internal 
mammary hotspols. The true location of the IM hotspot in the middle is specified in Figure 4. The 
lateral position (B) showed one additional axillary hotspot, not visible on the anterior-posterior 
view. The oblique view (C) showed no additional information. 
I SPECT/CT. An example of this kind of additional information provided by the 
SPECT/CT is depicted in Figures 3 and 4. 
In 7 patients the hot spot could not 
be linked to an anatomic substrate on the 
SPECT/CT due to non-nodal site of tracer 
accumulation. These sites of non-nodal 
tracer uptake were in the majority due to 
contamination of the skin with the 
radioactive tracer or a lymph tract near 
the injection site. 
Figure 4 Transaxial SPECT/CT images showing thai 
the location of the hotspot in the middle was not 
parasternal as suggested on the lymphoscintigraphy, 
but in the mediastinum just anterior to the aortic 
arch. 
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DISCUSSION 
In patients with breast cancer, the 1M nodal basin is a relatively common site of 
metastases. After successful harvesting of IM SNs, 22% shows metastatic 
involvement, in about one third without concomitant axillary metastases12. The 
presence of IM metastases represents a poor prognostic factor3. Although IM SN 
biopsy is not performed routinely, it contributes to adequate staging by 
identifying IM node-tumour positive patients. The less favourable prognosis in 
these patients thus can be influenced by tailoring their individual adjuvant 
treatment programs. 
The retrieval of IM SNs is often technically more challenging as compared 
to axillary SN biopsy and is associated with lower identification rates5. Failure 
in harvesting IM SNs is correlated with their small size, difficult anatomical 
localization, or limited radioactive tracer uptake4. In addition, the visualization 
rate of internal mammary nodes on lymphoscintigraphy is influenced by several 
different factors like site of tracer injection, the particle size and amount of the 
tracer used, the age of the patient and the localisation of the tumour13. 
Recently, SPECT/CT became available as a diagnostic tool in lymphatic 
mapping and SN biopsy. In order to determine its diagnostic value in 
visualizing and localizing SNs, we analysed our results in the initial 2 years 
period after introduction of SPECT/CT in our institute. In 50% of the patients, 
SPECT/CT resulted in the decision not to explore non-axillary hotspots as 
visualized on planar lymphoscintigraphic imaging, thereby avoiding surgical 
explorations that would not benefit the patient. 
As such, the additional use of SPECT/CT had a substantial influence on the 
subsequent surgical procedure. This advantage has not been described in 
similar research so far. 
Surprisingly, the lymphoscintigraphy showed to be more accurate than the 
SPECT/CT in two cases. In both patients, scanned in the beginning of the study, 
a parasternal hotspot on the scintigraphic images appeared retrosternal on the 
SPECT/CT. However, a hand-held gamma-ray detection probe suggested a 
parasternal location, which was confirmed by surgical exploration. This error of 
SPECT/CT can be explained by the imaging process. Although the position of 
the patient does not need to be changed for a SPECT/CT, the timing of the 
lymphoscintigraphic images and the CT images differs slightly. This can cause 
possible errors due to respiration and subsequent movement of the thorax. 
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The detection of additional SNs is reported as one the advantages of hybrid 
SPECT/CT in lymphatic mapping in patients with breast cancer8'11'14,15. In our 
patient population this was noted in two patients. The improved visualization 
rate is not only due to better contrast and resolution of SPECT as compared to 
conventional lymphoscintigraphy, but also because the CT has the ability to 
correct the SPECT signal for tissue attenuation. As a result, fused SPECT/CT 
images can detect hotspots, not visualised by planar lymphoscintigraphy. 
Another reported advantage of SPECT/CT is improved anatomical 
localization of the hotspots8"10. Although it is helpful for the surgeon to know 
the exact location of a hotspot, this will only be beneficial to the patient in case 
of clinical implications for the surgical procedure. For instance, in one patient 
the conventional images showed an intramammary SN, which turned out to be 
an axillary hotspot on SPECT/CT. In another patient, accumulation of 
radioactivity was seen in the presternal region, which was located parasternal 
on the SPECT/CT images. This lack of anatomic determination on the 
conventional images would have been corrected during surgery anyway, once 
the hand-held gamma probe was used. Therefore, this advantage of SPECT/CT 
has limited impact on the treatment of breast cancer patients. 
Considering the extra costs and time associated with SPECT/CT, we 
performed SPECT/CT only in case of IM hotspots. Van der Ploeg et al. also 
performed SPECT/CT selectively in difficult cases, in contrast to the other 
published studies, in which all consecutive patients were included8,9,11. 
Another important difference between our study and the available 
literature lies in the detection of additional axillary sentinel nodes. This can be 
explained by the technique used for conventional lymphoscintigraphy, since 
lymphatic mapping is influenced by several different factors like the dosage, 
volume and particle size of the radiocolloid, the duration of acquisition per 
view and the time of lymphoscintigraphy imaging post-injection. The reported 
identification rate for axillary hotspots ranges from 72-94% in these studies. In 
a consecutive series of 1008 patients, our visualization rate for axillary hot 
spots is 98%12. As a consequence, the added value of SPECT/CT to improve the 
identification rate for axillary SNs is limited in our patients. 
CONCLUS IONS 
IM SN biopsy contributes to improved staging in breast cancer. The results of 
lymphatic mapping of axillary and non-axillary SNs, as obtained by lympho-
scintigraphy, can be improved by the additional use of SPECT/CT. 
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Not only to improve localisation and increase the number of visualized SNs, 
but foremost, to reduce the number of unnecessary and potentially harmful 
explorations. 
As such, SPECT/CT has a considerable influence on surgical decision 
making, as compared to lymphoscintigraphy alone, in patients with breast 
cancer. 
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GENERAL D ISCUSS ION 
Sentinel lymph node (SN) biopsy has gained widespread acceptance as the 
preferred method to stage the axilla in breast cancer patients, although several 
questions have remained unanswered. With regard to the value of the internal 
mammary sentinel node biopsy there is much less consensus while even more 
technical issues have remained unresolved. 
This thesis has focused on aspects of both axillary and internal mammary 
SN biopsy to answer some of the most important questions. 
The studies presented in this dissertation are based on a detailed, single-
hospital patient registry. Though not level one evidence, research with such 
databases can provide important information on new diagnostic and 
therapeutic procedures, long before results from randomized controlled trials 
(RCT's) will be able to provide definitive answers. 
Axillary sentinel node biopsy 
The technique of SN biopsy is not yet standardised. Several studies have shown 
that performing a preoperative lymphoscintigraphy in combination with the 
intra operative use of a gamma detection probe and blue dye will achieve the 
highest identification rates. However, the success rate of the SN procedure is 
influenced by several other factors and there is still a search for new techniques 
to optimize the results. Additional tracer injection following initial scan failure 
(chapter 2) is a simple and effective way to improve the success rate of 
lymphoscintigraphy, without compromising its accuracy. Besides the study 
described in this thesis, there is only one other study available which mentions 
the use of additional tracer injection in case of non visualization of hotspots1. 
This study, by Cserni and colleagues, was conducted to compare two SN 
techniques, the blue dye guided lymphatic mapping method and a combination 
of the blue dye with a radiocolloid tracer. In case the lymphoscintigraghy did 
not show axillary hotspots after peritumoural injection of 50-60 MBq within 2-
3 hours post injection, a second, lower close (15-20 MBq) was given 
subareolarly. The additional tracer was administered in a limited number of 20 
patients. It is reasonable to assume that the lymphatic mapping technique used 
in our patients is superior; the amount of radioactivity of the initial tracer 
injection was higher (370 MBq) and the timing of lymphoscintigraphy post 
injection was longer in our lymphatic mapping protocol (12-16 hours). This 
could explain the improved visualization rate of 98%, as compared to 72% 
(52/72) in the referred study. However, if lymphatic mapping fails while using 
our protocol, other factors causing impaired lymphatic drainage seem to be 
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responsible, e.g. an increased BMI or advanced age. This can partly be resolved 
by additional tracer injection, without compromising the accuracy of the SN 
procedure. Recently, SPECT/CT came available as a new technique. Both 
SPECT/CT and an additional tracer injection may be applied in case of initial 
scan failure in order to identify a SN, thus preventing an unsuccessful SN 
procedure. However, considering the costs and time associated with SPECT/CT, 
we advocate the use of additional tracer injection as the preferred method for 
patients with absent visualisation of axillary hotspots. 
Another unresolved issue is the suitability of SN biopsy for certain 
subgroups of breast cancer patients. Conflicting results have been published for 
SN biopsy after previous excisional biopsy. Our results have shown that SN 
biopsy is reliable for these patients (chapter 3), with no false negative result in 
87 procedures, confirmed by completion axillary lymph node dissection. At the 
time these results were published, the eligibility of this subgroup of patients for 
lymphatic mapping was debated arguing that the lymphatic drainage could be 
altered with rerouting of the lymphatic flow towards a false "SN"2. This view 
could be substantiated in a study among 25 patients, showing lymphoscinti-
graphic images obtained before and after excision biopsy. In 17 of 25 patients 
a discrepancy in the drainage pattern after surgery was found. The authors 
therefore questioned the accuracy of SNB after excision biopsy and suggested 
that investigators performing SN biopsies in this specific group of patients 
should have long term follow-up data to record definitive axillary recurrence 
rates as the ultimate proof of accuracy. However, the gold standard for 
validation of the axillary SN procedure in breast cancer worldwide has been 
completion axillary lymph node dissection. Accordingly, validation of the SN 
procedure in this subgroup of patients should also be obtained by performing 
ALND, as described in chapter 3 of this thesis. One can speculate that the 
rerouting of lymphatic drainage after a diagnostic lumpectomy ultimately leads 
to the same.SN, as our results seem to indicate. 
In contrast, more recent results from the NSABP B-32 randomised phase 
III trial, found a false negative rate of 15.3% in 177 patients with previous 
incisional or excisional biopsy, compared to a false negative percentage of 
8.1% (48/589) in patients with a diagnostic core biopsy3. In this study, as well 
as in our study, a completion axillary lymph node dissection was performed in 
all patients to determine the accuracy of the SN procedure in this subgroup. 
However, there are two important differences between the two studies. One is 
the amount of radioactivity used. We applied 370mBq (10 mCi) compared to 
37 mBq (1 mCi) in the participants of the NSABP B-32 trial. The second, 
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probably most important difference is the fact that a preoperative 
lymphoscintigraphy was not mandatory in this trial. As a result, the true number 
of SNs may be missed and consequently the "true" SN might not have been 
identified. These differences in technical aspects may explain the unacceptably 
high false negative percentage in the NSABP B-32 trial. Based on our 
observations it is reasonable to conclude that a SN procedure can safely be 
performed in the subgroup of patients with a previous excisional biopsy, so that 
these patients will not be deprived of the advantages of the SN procedure. 
Special attention should be given to performing preoperative lymphoscinti-
graphies and to the amount of tracer injected. First and foremost, however, one 
should aim to establish a histopathologic diagnosis preoperatively using less 
invasive diagnostic techniques thus avoiding diagnostic surgical breast biopsies. 
It is generally accepted that an axillary clearance may be omitted in case 
of a negative SN procedure. However, in a limited percentage of cases SN 
biopsy fails to identify existing axillary metastases. This may in turn result in 
axillary recurrences and distant metastases. With long term follow-up results 
Table 1 Axilllary recurrence after negative SN biopsy without ALND 
Author Year No. of Median follow-up Axillary 
Patients (months) recurrences 
Blanchard4 2003 685 29 1(0.1 %) 
Jeruss5 2005 592 27 1(0.2%) 
Smidt6 2004 439 26 2(0,5%) 
Naik7 2004 2340 31 3(0.13%) 
Veronesi8 2005 953 38 3(0,3%) 
Zavagno9 2005 479 36 0 
Swenson10 2005 612 33 3(0.5%) 
Palesty" 2006 335 33 2(0.6%) 
Heuts12 2007 344 43 3(0,9%) 
Takei13 2007 822 36 4(0,5%) 
Berkvist"1 2008 2246 37 27(1,2%) 
Van der Ploeg'5 2008 748 46 2(0,25%) 
VanWely15 2008 392 65 11(2,8%) 
Poletti" 2008 804 39 7(0,87%) 
Veronesi18 2009 3548 48 31(0,87%) 
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now becoming available a comparison of the prevalence of axillary recurrences 
in our study cohort with data from other studies is feasible (chapter 4). More 
recent literature confirms our conclusions that the rate of axillary recurrence in 
patients with a negative SN biopsy is low and better than expected. An update 
of the axillary recurrences rale after negative SN biopsy in studies with more 
than 300 patients is presented in Table 1. 
These numbers imply that an axillary lymph node dissection can safely be 
omitted in case of a tumour negative SN biopsy. 
Internal mammary sentinel node biopsy 
The presence of a lymphatic drainage pathway of the breast to Ihe internal 
mammary nodes, as well as the frequency and prognostic importance of 
tumour involvement in this lymphatic basin has been confirmed by numerous 
studies''12". As a consequence, internal mammary lymph node dissection was 
part of the standard surgical treatment in the 1950s and 1960s. Randomized 
trials indeed showed unfavourable survival rates for patients with IM 
metastases, but no improvement of the prognosis after radical dissection of the 
internal mammary chain. As a consequence, internal mammary dissection was 
abandoned in the 1970s. 
Following the introduction of the SN technique, the internal mammary 
basin has regained interest. IMSN biopsy is feasible and it adds to the adequate 
staging by identifying IM node tumour-positive patients (chapter 5). The obvious 
question is whether identification of IMSNs, biopsy of those nodes, the 
subsequent upstaging, and the change in management will translate into 
improved survival. We tried to answer this difficult question in chapter6. Of the 
764 patients studied, only 28 had tumour-positive IM nodes and of them 7 had 
tumour-negative axillary nodes. Although we were able to demonstrate a 
tendency to improved survival following adjusted treatment regimens in 
patients with proven IM metastases, these numbers were too small to draw 
definite conclusions about any survival gain by tailored treatment of this group. 
Much larger series and longer follow-up will be needed to give a final answer 
to this question. It is questionable whether these studies will ever be 
achievable, considering the small number of patients with IM metastases and 
an even smaller part with solitary IM metastases. Meanwhile, the fact that 
multiple studies have consistently found that medial breast cancers carry a 
worse prognosis compared to lateral cancers, even after adjusting for other 
known prognostic factors, seems to indicate some deficiency in staging and 
subsequent undertreatment. We therefore bel ieve, that IMSN biopsy can 
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improve nodal staging by identifying higher- risk patients with IM metastases, 
who may benefit from adjuvant therapy, which in turn may lead to survival 
benefit21"23. This individualised, tailored adjuvant therapy of patients with IM 
metastases is in perfect harmony with the current trend of more personalized 
patient treatment. Performing an IMSN biopsy is dependent on the visualization 
of IM hotspots on the preoperative lymphoscintigraphic images. The incidence 
of IM drainage varies and is affected by several factors. Site of tracer injection, 
particle size and amount of tracer used, age of the patient and localisation of 
the tumour are all examples of these independent factors. However, increasing 
the time interval between injection of the radioactive tracer and 
lymphoscintigraphy does not affect the visualization rate of internal mammary 
hotspots (chapter 7). 
The retrieval of IM SNs is often technically challenging as compared to 
axillary SN biopsy and is associated with lower identification rates. Failure to 
harvest IM SNs is correlated with their small size, difficult anatomical 
localization, or limited radioactive tracer uptake. SPECT/CT (Single-Photon 
Emission Computed Tomography/Computed Tomography) is currently available 
to improve the visualization of hotspots and determine their exact anatomical 
location. The number of reports on the use of SPECT/CT in lymphatic mapping 
for breast cancer is limited. The reported advantages are the determination of 
the exact anatomical location of the SNs and the detection of additional SNs. 
Flowever, the results of our study indicate that the most important advantage of 
additional SPECT/CT for patients with IM hotspots is the reduction of the 
number of unsuccessful explorations, because of an unaccessible localization 
of the IMSN (chapter 8). 
Future perspectives 
Whether axillary clearance is of any benefit for node-positive patients in terms 
of survival is not known yet. The development and more widespread use of 
chemotherapy, hormonal therapy and monocolonal antibodies have not only 
reduced the mortality from breast cancer, but also the risk of local recurrence. 
The role of ALND in node positive patients to achieve these goals is the subject 
of the American College of Surgeons Oncology Group (ACOSOG) Z0011 
trial24. This ongoing trial is randomising SN-positive patients between ALND 
and observation of the axilla. 
Other interesting questions that are currently being investigated include 
besides the suitability of SN biopsy for patients with previous excisional biopsy, 
which was addressed in this thesis, other questionable exclusion criteria for SN 
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biopsy like multicentric or recurrent breast cancer and preoperative 
radiotherapy to the breast. The accuracy of the SN procedure in case of 
recurrent breast cancer is being studied in the SNARB study (Sentinel Node And 
Recurrent Breast cancer). As a part of this Dutch study SN biopsy following 
previous breast radiotherapy will be investigated. 
Another point of debate is the clinical relevance of micro metastases (0.2 
mm- 2.0mm) and isolated tumour cells (<0.2 mm) in the SN, since more and 
smaller metastases are encountered with the use of step-sectioning and 
immunohistochemical staining. Before the introduction of the SN procedure, 
these metastases remained undetected. It remains unclear whether these few 
malignant cells have the potential to grow into palpable nodes and whether 
they can be the source of distant metastases. The MIRROR study is currently 
evaluating the impact of adjuvant therapy on disease-free survival for patients 
with micrometastases and isolated tumour cells. The first results of this study 
imply that breast cancer patients with isolated tumour cells (ITC) or micro 
metastases as final N-stage after a SN biopsy have a worse 5-year disease free 
survival as compared to patients having no ITCs or micro metastases, 
independent of primary tumour characteristics25. 
A new promising development in breast cancer management is the 
introduction of gene expression profiling using microarray hybridization. The 
genomic information may be able to refine prognosis, and to improve 
therapeutic strategies for breast cancer patients26,27. For now, whether 
microarray gene-expression profiling for breast-cancer prognosis is better than 
our current prognostic markers, including those determined by SN biopsy, 
remains an open question. Further studies are necessary to develop and 
improve this new technique. 
In the near future new MRI (Magnetic Resonance Imaging) techniques 
might be able to detect and localise SNs28. Future investigators might produce 
a contrast agent to determine the metastatic nature of a lymph node in breast 
cancer patients on MRI images, as is currently evaluated for other 
malignancies29,30. However, the detection of micrometastases and isolated 
tumour cells with imaging-techniques seems to be far fetched for now. As a 
consequence SN biopsy will probably remain an essential part of breast cancer 
staging. 
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CONCLUD ING REMARKS 
Sentinel node biopsy has played a significant role in the evolution of breast 
cancer treatment in the past decade. It has replaced ALND in case of a tumour 
negative SN biopsy, as the preferred method to stage the axilla, thereby 
avoiding unnecessary morbidity associated with ALND. The SN procedure is a 
perfect example of the current trend for more minimally invasive diagnostic and 
therapeutic procedures. The future will teach us if the prognostic role of SN 
biopsy will gradually be replaced by a combination of primary tumour 
characteristics and non-invasive imaging of the axilla. 
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SUMMARY 
The aim of this thesis was to evaluate technical aspects, clinical implications 
and outcome several aspects of the sentinel node procedure and determine the 
clinical implications of axillary and internal mammary sentinel node biopsy in 
patients with breast cancer. 
In Chapter 1, an introduction on sentinel node biopsy in breast cancer is 
provided as well as the outline of the thesis. 
Several studies have shown that lymphoscintigraphy, in combination with 
the intra operative use of a gamma detection probe, blue dye and radioactive 
tracer will achieve the highest SN identification rates. However, sometimes 
lymphatic mapping fails to show a hotspot, because of insufficient or absent 
radioactive tracer uptake in the lymph nodes. In Chapter 2 we evaluated the 
use of re-injections of 37 MBq tracer intracutaneously in cases of initial scan 
failure in order to increase the technical success rate of the sentinel node 
procedure. A total of 1208 patients with clinically node-negative breast cancer 
were included in this study. In 93 patients (7.7%) visualization of hotspots on 
initial lymphoscintigraphy was insufficient (41 patients) or absent (52 patients). 
The first 14 patients did not receive additional tracer injection. In 5 patients, 
additional tracer injection did not result in successful lymphoscintigraphy, 
which is correlated with massive nodal tumour infiltration. In 33 patients with 
negative initial lymphoscintigraphy, additional tracer injection resulted in 
secondary SN visualization. Almost half of these patients had a negative SN and 
could be spared an unnecessary axillary lymph node dissection (ALND). In 41 
patients with faint hotspots on initial lymphoscintigraphy, additional tracer 
injection, by increasing nodal uptake, simplified an accurate SN biopsy. 
Decreased radiotracer uptake in this group was associated with older age and 
high BMI. In conclusion, we demonstrated that additional tracer injection is 
helpful to visualize hotspots in case of insufficient uptake of radioactive tracer 
in the sentinel node. However, if lymphatic mapping, even after additional 
tracer injection, fails to show axillary hotspots, axillary dissection should be 
performed because of the substantial risk of massive tumour infiltration. 
Sentinel node (SN) biopsy has become the standard of care in the 
treatment of breast cancer, but several controversial issues remain. Scepticism 
persists about the accuracy of SN biopsy following previous excisional biopsy. 
It is assumed that the lymphatic drainage pattern is altered in these patients, 
resulting in less accurate lymphatic mapping and unreliable results of the SN 
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biopsy. If this hypothesis is correct, then a number of breast cancer patients will 
not experience of the advantages of the SN technique. In Chapter 3, we 
reviewed the results of SN biopsy in a total of 88 patients, who had previously 
undergone diagnostic excisional biopsy followed by complete axillary lymph 
node dissection. Lymphoscintigraphy visualized one or more axillary hot spots 
in 84 of the 88 patients. A successful SN biopsy was performed in 87 patients. 
Complete axillary lymph-node dissection showed no false-negative SN biopsy 
among the 87 SN procedures. Consequently, the sensitivity of SN biopsy 
following previous excisional biopsy in this study was 100%. Therefore, these 
results indicate that patients with previous excisional biopsy are eligible for the 
sentinel node procedure and can be spared an unnecessary axillary lymph 
node dissection, if found to be node-negative. 
During the learning phase of the sentinel node procedure, false-negative 
results came to light by confirmatory axillary lymph node dissection. 
Nowadays, sentinel node negative patients do not receive elective ALND, with 
acceptance of a false negative rate of 5%. This implies that a number of patients 
will develop an axillary recurrence. It therefore remains important to evaluate 
long-term follow-up results, especially with respect to axillary relapse as an 
indicator of a false-negative SN procedure. 
In Chapter 4 we evaluated the results of SLNB with respect to locoregional 
failures in the axilla in SN-negative patients. Published studies on this subject 
showed axillary relapse risks ranging from 0% to 1.5% after a median follow-
up of 14 to 57 months. Our own results, with an axillary recurrence risk of 
0.9% after a median follow up of 43 months, are in accordance with these 
studies. Our own data, as well as that of the published series, found axillary 
recurrence to be less than expected. Although longer follow-up is required, 
these midterm follow-up data support the current opinion that ALND can be 
safely abandoned in case of a negative SN biopsy. 
In spite of the fact that the preferential lymphatic drainage pathway from 
the breast is into the axilla, there are other locations to which metastatic tumour 
cells migrate. The second most important draining route from the breast is 
towards the internal mammary lymph nodes (IMN). This regional nodal basin 
has been studied intensively in the 1950's and 1960's. These studies showed 
that, in addition to the axillary lymph node status, the IM lymph node status 
provides important prognostic information in breast cancer patients. If positive, 
prognosis is less favorable. However to date, when lymphatic mapping reveals 
IM drainage, staging of these nodes is not performed routinely. 
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In Chapter 5 we evaluated the relevance of IMSN biopsy as a method to 
improve staging in a total of 1008 consecutive patients. In this study, both 
axillary and IMSNs were sampled, based on lymphoscintigraphy, intraoperative 
gamma probe detection and blue dye mapping. Lymphoscintigraphy showed 
axillary sentinel nodes in 98% (989/1008) and IMSNs in 20% of the patients 
(196/1008). Sampling of the IM basin, as based on the results of 
lymphoscintigraphy, was successful in 71% of the patients (139/196) and 
revealed metastases in 22% (31/139). In 29% percent of the patients with 
positive IMSNs (9/31) no axillary metastases were found. With respect to the 
clinical relevance of IMSN biopsy, adjuvant treatment strategies were changed 
in all patients with IM metastases, by receiving adjuvant radiotherapy of the IM 
lymph node basin. Besides adjuvant radiotherapy, adjuvant chemotherapeutic 
regimes were changed in a small group of patients. Thus, IMSN biopsy 
improves nodal staging in breast cancer patients. 
Although several studies have shown that IMSN biopsy enables identifying 
and selectively removing IMSNs with minimal morbidity, controversy remains 
regarding its clinical relevance and the expected benefit. We conducted a study 
to determine the usefulness of IMSN biopsy in terms of survival benefit. The 
results of this study are presented in Chapter 6. Data from 764 patients with a 
minimal follow up of one year were available. A total of 406 patients had no 
lymph node metastases (group 1), 330 patients had axillary metastases (group 2), 
7 patients had IM metastases only (group 3) and 21 patients had both axillary and 
IM metastases (group 4). Mean follow-up was 46 months. Breast cancer specific 
survival was 95% for group 1, 84% for group 2, 82% for group 3 and 89% for 
group 4. Disease-free survival was 92%, 81%, 86% and 90%, respectively. The 
differences between group 2, 3 and 4 were not statistically significant. Our results 
suggest that high risk patients with IM metastases benefit from improved staging 
and tailored adjuvant treatment algorithms. However, long-term follow-up data, 
preferably in larger series, are needed to support our findings. 
There is a wide range of reported success rates of internal mammary 
hotspot visualization. Results differ mainly, because the detection rate is 
influenced by several technical, anatomical and biological factors. The aim of 
the study presented in Chapter 7 was to investigate whether different time 
intervals between injections of a radioactive tracer and performing 
lymphoscintigraphy affect the visualization rate of internal mammary hotspots. 
A total of 682 eligible breast cancer patients underwent sentinel lymph node 
mapping. The technique involved the injection of 370 MBq (10 mCi) Tc-99m 
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nanocolloid peritumorally. In 470 patients (group A) the time interval between 
injection of the radiocolloid and lymphoscintigraphy was 16 hours, compared 
to 2.5 hours in 212 patients (group B). Axillary hotspots were visualized in 97% 
in group A and 96% in group B. Lymphoscintigraphy showed internal 
mammary hotspots in 21% in group A, compared to 27% in group B, which is 
not statistical significant. Thus, in this study, we could not demonstrate a 
correlation between timing of the radiotracer injection and the 
lymphoscintigraphic detection of IM sentinel nodes. 
Recently, SPECT/CT (Single-Photon Emission Computed Tomography/ 
Computed Tomography) came available as a new, non-invasive technique that 
combines the functional information of SPECT with the anatomical information 
provided by CT. Chapter 8 focuses on the use of SPECT/CT as compared to 
conventional lymphoscintigraphy alone, in patients with breast cancer with IM 
hotspots on lymphoscintigraphy. Forty-two consecutive patients were included. 
In 16 patients (38%), the SPECT/CT provided no additional information 
compared to lymphoscintigraphy alone. In 5 patients (12%) SPECT/CT provided 
additional information, but without surgical consequences. In the remaining 21 
patients (50%) the SPECT/CT results had a substantial impact on the surgical 
procedure. In 2 patients (4.8%), the SPECT/CT showed additional SNs. In 20 
patients (47.6%) the SPECT/CT results gave substantial reason not to explore the 
SN as visualised on the lymphoscintigraphy. From our results, it can be 
concluded that SPECT/CT improves the localisation and increases the number 
of visualized SNs. But foremost, SPECT/CT reduces the number of unnecessary 
and potentially harmful explorations in patients with alleged IM hotspots on 
lymphoscintigraphy, which on SPECT/CT proved to be in aberrant positions 
Sentinel node biopsy has played a significant role in the evolution of 
breast cancer treatment in the past decade. It has replaced ALND in case of a 
negative SN biopsy, as the preferred method to stage the axilla, thereby 
avoiding unnecessary morbidity associated with ALND. The SN procedure is a 
perfect example of the current trend for more minimally invasive diagnostic and 
therapeutic procedures. 
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SAMENVATTING 
Het doel van dit proefschrift was om verschillende aspecten van de 
schildwachtklierprocedure te evalueren en om de klinische consequenties van 
zowel de axillaire als parasternale schildwachtklierbiopsie bij patiënten met 
borstkanker vast te stellen. 
In Hoofdstuk 1 wordt een introductie over de schildwachtklierbiopsie bij 
borstkanker gegeven en wordt de opzet van het proefschrift beschreven. 
Verschillende studies hebben aangetoond, dal een lymfoscintigrafie in 
combinatie met een blauwe kleurstof, een radioactieve tracer en het intra-
operatieve gebruik van een gamma detectie probe de meest betrouwbare 
methode is om de schildwachtklier te identificeren. 
Soms is er echter geen hot spot zichtbaar op de lymfoscintigrafie, vanwege 
afwezige of onvoldoende opname van radioactief materiaal in de lymfeklieren. 
In Hoofdstuk 2 evalueren we of bijspuiten met een intracutane injectie 
van 37 MBq in geval van afwezige of onvoldoende visualisatie van hot spots op 
de lymfoscintigrafie het succespercentage van de schildwachtklierprocedure 
kan vergroten. In totaal werden 1208 klinisch okselklier negatieve borstkanker 
patiënten in deze studie geïncludeerd. Bij 93 patiënten (7,7%) was de 
visualisatie van hotspots op de oorspronkelijke lymfoscintigrafie onvoldoende 
(41 patiënten) of afwezig (52 patiënten). De eerste 14- patiënten werden niet 
bijgespoten. Bij 5 patiënten leverde bijspuiten geen succesvolle lymfoscinti-
grafie op, hetgeen correleerde met de aanwezigheid van uitgebreide 
tumorgroei in de lymfeklier. Bij 33 patiënten met een aanvankelijk negatieve 
lymfoscintigrafie resulteerde bijspuiten alsnog in schildwachtkliervisualisatie. 
Bijna de helft van deze patiënten had een negatieve schildwachtklier waardoor 
hen een onnodig okselkliertoilet bespaard kon worden. Bij 41 patiënten met 
vage hot spots op de initiële lymfoscintigrafie, werd door verbeterde opname 
na additionele tracer injectie, een eenvoudige en betrouwbare schildwacht-
klierprocedure mogelijk gemaakt. Verminderde opname van de radioactieve 
tracer was in deze groep geassocieerd met hogere leeftijd en een hoge BMI. In 
deze studie is aangetoond, dat bijspuiten een zinvolle bijdrage levert bij het 
visualiseren van hotspots indien er sprake is van onvoldoende opname van 
tracer in de schildwachtklier. Evenwel, als lymfoscintigrafie, ook na bijspuiten 
geen axillaire hot spots laat zien, dan is een okselklierdissectie geïndiceerd, 
omdat er een substantieel risico is op uitgebreide tumorgroei in de oksel. 
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De schildwachtklierprocedure is de standaard behandeling geworden bij 
patiënten met borstkanker, maar er zijn nog verschillende controversiële 
onderwerpen. Nog steeds worden er vraagtekens geplaatst bij de 
betrouwbaarheid van de schildwachtklier-procedure na een voorafgaande 
diagnostische lumpectomie. Er wordt verondersteld, dat bij deze groep 
patiënten het lymfedrainagepatroon gewijzigd is en dat daardoor het resultaat 
van de schildwachtklierprocedure minder betrouwbaar zou zijn. Als deze 
hypothese juist is, zou een aantal borstkankerpatiënten niet kunnen profiteren 
van de voordelen van de schildwachtkliertechniek. 
In Hoofdstuk 3, bespreken we de resultaten van de schildwacht-
klierbiopsie in een groep van 88 patiënten, die eerder een diagnostische 
lumpectomie hebben ondergaan, gevolgd door een okselkliertoilet. De 
lymfoscintigrafie toonde een of meer axillaire hot spots bij 84/88 patiënten. Bij 
87 patiënten vond een succesvolle schildwachtklierprocedure plaats. De 
okseldissectie toonde geen fout-negatieve procedure aan bij deze 87 patiënten. 
Dientengevolge was de sensitiviteit van de schildwachtklierprocedure na een 
voorafgaande diagnostische lumpectomie in deze studie 100%. Derhalve 
komen ook patiënten na een diagnostische lumpectomie in aanmerking voor de 
schildwachtklierprocedure en kan de klier-negatieve patiënten een onnodig 
okselkliertoilet bespaard worden. 
Tijdens de leercurve van de schildwachtklierprocedure kwamen fout-
negatieve resultaten aan het licht door het aanvullend verrichte okselkliertoilet. 
Tegenwoordig wordt het okselkliertoilet achterwege gelaten bij patiënten met 
een negatieve schildwachtklier, waarbij 5% fout-negatieve procedures als 
acceptabel worden beschouwd. Dit houdt in, dat bij een aantal patiënten zich 
een okselrecidief zal ontwikkelen. Het blijft daarom belangrijk de lange termijn 
follow-up te evalueren, vooral omdat een okselrecidief kan duiden op een fout-
negatieve schildwachtklierprocedure. 
In Hoofdstuk 4 evalueren we de resultaten van de schildwachtklier-
procedure met betrekking tot de locoregionale recidieven in de oksel bij 
patiënten met een negatieve schildwachtklierbiopsie. Gepubliceerde studies 
over dit onderwerp vermelden okselrecidieven met uiteenlopende percentages 
van 0% tot 1,5% na een mediane follow-up van 14 tot 57 maanden. Onze 
eigen resultaten, 0,9% okselrecidieven na een mediane follow-up van 43 
maanden, stemmen overeen met deze studieresultaten. Onze eigen gegevens, 
evenals die van de voornoemde publicaties, laten minder locoregionale 
recidieven zien, dan men zou verwachten. Hoewel een langere follow-up 
periode noodzakelijk is, ondersteunen deze middellange follow-up gegevens 
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de heersende opvatting, dat een okselkiiertoilet veilig achterwege gelaten kan 
worden bij een negatieve schildwachtklierprocedure. 
Ondanks het gegeven, dat de lymfedrainage van de borst bij voorkeur 
verloopt naar de oksel, zijn er andere locaties, waarnaar tumorcellen kunnen 
migreren. Lymfdrainage naar de parasternale lymfeklieren is, naast de axilla, de 
meest voorkomende drainageroute van de borst. Dit regionale klierstation is in 
de jaren '50 en '60 onderwerp van meerdere studies geweest. Deze studies 
tonen aan, dat -naast de status van de okselklieren- de lymfeklierstatus van het 
parasternale klierstation belangrijke prognostische informatie levert bij 
patiënten met borstkanker. Bij positieve parasternale lymfeklieren is de 
prognose ongunstig. Tot op heden is stagering van parasternale lymfeklieren 
evenwel geen routine. 
In Hoofdstuk 5 evalueren we de waarde van de parasternale lymfeklier-
biopsie als methode ter verbetering van de stagering in een groep van 1008 
achtereenvolgende patiënten. In deze studie, werden zowel axillaire als 
parasternale schildwachtklieren gebiopleerd op basis van lymfoscintigrafie, 
intra-operatieve detectie met een gamma probe en een blauwe tracer. 
Lymfoscintigrafie liet axillaire schildwachtklieren zien in 98% (989/1008) en 
parasternale klieren in 20% van de patiënten (196/1008). Het verrichten van 
een parasternale schildwachtklierbiopsie op basis van de resultaten van de 
lymfoscintigrafie, was succesvol in 71% van de patiënten (139/196) en toonde 
metastasen aan in 22% (31/139). In 29% van de patiënten met positieve 
parasternale schildwachtklieren (9/31) bleken de axillaire schildwachtklieren 
negatief. Gezien het belang van de parasternale kiierstatus, werd de 
behandeling van alle patiënten met parasternale metastasen aangepast. Zij 
kregen aanvullende bestraling op de parasternale lymfeklieren. Behalve 
aanvullende bestraling, werd bij een kleine groep patiënten ook de 
chemotherapie aangepast. Derhalve wordt de stagering van borstkanker-
patiënten verbeterd door parasternale schildwachtklierbiopsie. 
Hoewel verschillende studies hebben aangetoond, dat het verrichten van 
een parasternale schildwachtklierbiopsie met geringe morbiditeit mogelijk is 
blijven er controversies bestaan wat betreft de klinische relevantie en het te 
verwachten voordeel. W e onderzochten een groep patiënten om de betekenis 
van parasternale klierbiopsie met betrekking tot overleving vast te stellen. De 
resultaten van deze studie worden gepresenteerd in Hoofdstuk 6. Gegevens van 
764 patiënten met een minimale follow-up van één jaar waren beschikbaar. 
Binnen deze groep hadden 406 patiënten geen lymfekliermetastasen (groep 1), 
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330 patiënten hadden axiliaire metastasen (groep 2), 7 patiënten hadden alléén 
parasternale metastasen (groep 3) en 21 patiënten hadden zowel axiliaire als 
parasternale metastasen (groep 4). De mean follow-up was 46 maanden. 
Borstkanker specifieke overleving was 95% voor groep 1, 84% voor groep 2, 82% 
voor groep 3 en 89% voor groep 4. Ziektevrije overleving was respectievelijk 92%, 
81%, 86% en 90%. De verschillen tussen groep 2, 3 and 4 waren niet statistisch 
significant. Onze resultaten suggereren, dat patiënten met een hoog risico 
vanwege parasternale metastasen gebaat zijn bij verbeterde stagering en op maat 
gesneden adjuvante therapieschema's. Lange termijn follow-up gegevens, bij 
voorkeur in grotere series, zijn noodzakelijk om onze bevindingen te 
ondersteunen. 
Er is een scala aan publicaties over het succespercentage bij de visualisatie 
van parasternale hot spots. De resultaten verschillen voornamelijk, omdat de 
detectie ratio wordt beïnvloed door verschillende technische, anatomische en 
biologische factoren. Het doel van de studie, welke in Hoofdstuk 7 wordt 
gepresenteerd, was te onderzoeken of een verschillende tijdsduur tussen het 
injecteren van de radioactieve tracer en het tijdstip van de lymfoscintigrafie van 
invloed zou zijn op mate van visualisatie van parasternale hot spots. Een groep 
van 682 borstkankerpatiënten onderging de schildwachtklierprocedure. De 
techniek omvatte het injecteren van 370 MBq (10 mCi) Tc-99m nanocolloid 
rond de tumor. Bij 470 patiënten (groep A) was de tijdsduur tussen injectie van 
het radiocolloid en de lymfoscintigrafie 16 uur, in vergelijking tot 2,5 uur bij 212 
patiënten (groep B). Axiliaire hot spots werden zichtbaar in 97% van groep A 
and in 96% van groep B. Lymfoscintigrafie liet parasternale hot spots zien bij 
21% in groep A, vergeleken met 27% in groep B. Dit verschil is niet statistisch 
significant. In deze studie konden wij derhalve geen correlatie aantonen tussen 
het tijdstip van de tracerinjectie en de lymfografische detectie van parasternale 
hot spots. 
Onlangs kwam de SPECT/CT (Single-Photon Emission Computed Tomo-
graphy/Computed Tomography) beschikbaar als een nieuwe, niet-invasieve 
techniek, die de functionele informatie van SPECT combineert met de 
anatomische informatie van de CT. Hoofdstuk 8 richt zich op het gebruik van 
SPECT/CT in vergelijking met de conventionele lymfoscintigrafie, bij borst-
kankerpatiënten met parasternale hot spots op de lymfoscintigrafie. Twee-
enveertig achtereenvolgende patiënten werden geïncludeerd. Bij 16 patiënten 
(38%), verschafte de SPECT/CT geen aanvullende informatie in vergelijking met 
lymfoscintigrafie alleen. Bij 5 patiënten (12%) leverde de SPECT/CT additionele 
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informatie op, maar dit leidde niet tot chirurgische consequenties. Bij de 
overige 21 patiënten (50%) maakten de SPECT/CT resultaten een substantieel 
verschil uit voor het chirurgisch handelen. In 2 patiënten (4,8%), liet de 
SPECT/CT extra schildwachtklieren zien. In 20 patiënten (47,6%) gaven de 
SPECT/CT resultaten doorslaggevende redenen om de schildwachtklieren, 
gevisualiseerd op de lymfoscintigrafie niet te biopteren. Op basis van onze 
resultaten, kan worden geconcludeerd, dat SPECT/CT de lokalisatie en het 
aantal gevisualiseerde schildwachtklieren verbetert. Maar meer nog, de 
SPECT/CT vermindert het aantal onnodige en mogelijke morbiditeit verhogende 
exploraties bij patiënten met zogenaamde parasternale hot spots op de 
lymfoscintigrafie, die in SPECT/CT zich op een aberrante positie blijken te 
bevinden. 
In de afgelopen 10 jaar heeft de schildwachtklierbiopsie een belangrijke 
rol gespeeld in de ontwikkeling van de behandeling van borstkanker. De 
schildwachtklierbiopsie heeft het okselkliertoilet vervangen als de standaard 
techniek voor de stagering van klier-negatieve patiënten, waardoor onnodige 
morbiditeit gerelateerd aan het okselkliertoilet kan worden vermeden. De 
schildwachtklierbiopsie is een goed voorbeeld van de trend richting minimaal 
invasieve diagnostische en therapeutische procedures. 
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DANKWOORD 
Het is zover, "het boekje" is af. Het schrijven van dit proefschrift is te 
vergelijken met de multidisciplinaire behandeling van het mammacarcinoom. 
Door intensieve samenwerking tussen de verschillende specialismen wordt 
gestreefd naar een snelle diagnose en adequate behandeling van patiënten met 
borstkanker. Zowel voor het tot stand komen als voor de afronding van dit 
proefschrift geldt eveneens dat er meerdere personen met mij hebben 
samengewerkt om tot dit eindresultaat te komen. Graag wil ik een aantal 
mensen in het bijzonder bedanken voor hun bijdrage. 
Allereerst wil ik Dr. van der Ent, mijn co-promotor van harte bedanken. Fred, 
je grote betrokkenheid, inspiratie, geduld en je vertrouwen in mij zijn essentieel 
geweest om dit project af te ronden. Mijn eerste schiIdwachtklierbiopsie heb ik 
verricht onder jouw supervisie. Destijds had ik nooit gedacht dat jouw 
enthousiaste uitleg de basis zou zijn voor deze promotie. Jouw bijdrage is dan ook 
van onschatbare waarde. 
Veel dank ben ik ook verschuldigd aan mijn tweede co-promotor, Dr. Voogd. 
Beste Adri, jouw statistische kennis zorgde voor onze eerste kennismaking. Daarna 
heb ik dankbaar gebruik gemaakt van je wetenschappelijke kennis en je nimmer 
aflatende bereidheid om over verschillende aspecten van het onderzoek mee te 
denken. Dankjewel voor de vruchtbare en gezellige samenwerking. 
Prof. dr. von Meyenfeldt. Maarten, ondanks je overvolle agenda heb je 
toch de tijd gevonden en de rust genomen om mee te denken over de artikelen 
en hoofdstukken van het manuscript. Bedankt voor je begeleiding. Daarnaast 
hoop ik de komende maanden op oncologisch gebied ook nog het nodige van 
je te leren. 
Prof. dr. Tjan-Heijnen, bedankt voor het aanvaarden van de rol van 
voorzitter van de beoordelingscommissie van mijn proefschrift. Naast de 
voorzitter wil ik ook de andere leden van de beoordelingscommissie bedanken. 
Prof. dr. Teule, Prof. dr. Rutgers en Dr. Boersma, bedankt voor het kritisch lezen 
en becommentariëren van het proefschrift. 
Prof. dr. Cserni, dear Gabor, 1 would like to thank you for reviewing my 
PhD Thesis. 
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Mijn paranimfen, Igna en Edith. Igna, het was een logische keuze om jou te 
vragen als paranimf. Je bent bij alle stadia van het onderzoek betrokken 
geweest en je hebt de nodige avonden en weekenden zonder je echtgenoot 
moeten doorbrengen, omdat hij weer eens een artikel moest reviseren. Bedankt 
voor je tijd, oprechte interesse op alle gebied en gezelligheid. Edith, als 
chirurgie-maatje hebben we al een aantal jaren samengewerkt. Dit houdt in de 
praktijk in dat we elkaar soms meer hebben gezien dan onze eigen familie. 
Bedankt voor je hulp en luisterend oor in de slotfase van het onderzoek. 
Ook een woord van dank voor de secretaresse van Maarten, Joyce Haas, 
die een beetje "mijn" secretaresse is geweest. Zowel afspraken met Maarten als 
alle formulieren en telefoontjes over de promotie heb je geweldig geregeld. 
Ik wil ook al mijn collega's van het Maastricht Universitair Medisch 
Centrum (MUMC+) bedanken voor de geboden gelegenheid het proefschrift af 
te ronden. 
De maatschap chirurgie in Sittard met in het bijzonder drie chirurgen, Dr. 
Hoofwijk, Dr. Hulsewé en Dr. Heeren. Ton, dankzij jouw vooruitziende blik en 
motiverende enthousiasme is er nu toch echt een promotie. Karei en Michiel, 
bedankt voor jullie medewerking aan het onderzoek en bijdragen aan de 
diverse manuscripten. 
Bijzondere dank ben ik ook verschuldigd aan twee nucleair 
geneeskundigen, Drs. van de Pol en Dr. Kengen. Beste Harry en Roland, jullie 
nucleair geneeskundige kennis vormt mede de basis van dit proefschrift. Dank 
voor jullie inzet en plezierige samenwerking. 
Mijn vader en moeder wil ik bedanken voor hun onvoorwaardelijke steun. 
Zonder jullie was dit boekje er nooit geweest. Mijn drietal mag blij zijn met 
zo'n opa en oma! 
Mijn drie wondertjes: Sterre, Lieve en Melle...eindelijk is het boekje van 
mamma af....gelukkig wil pappa niet promoveren. 
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